


3



(19) Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) EP 1 471 144 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
27.10.2004 Bulletin 2004/44(51) Int Cl.⁷: C12N 15/12, C07K 14/715,
C12Q 1/68, G01N 33/68,
G01N 33/566, A61K 38/17,
C12N 5/10, C12N 15/11

(21) Application number: 04013403.3

(22) Date of filing: 02.12.1997

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE(72) Inventor: The designation of the inventor has not
yet been filed(30) Priority: 02.12.1996 US 32224 P
01.12.1997 US 980872(74) Representative: HOFFMANN EITLE
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München (DE)(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
97953072.2 / 0 942 979

Remarks:

This application was filed on 07 - 06 - 2004 as a
divisional application to the application mentioned
under INID code 62.(71) Applicant: MAGAININ PHARMACEUTICALS INC.
Plymouth Meeting PA 19462 (US)(54) Biological variability of asthma associated factor, AAF2 (IL-9 receptor), useful in treating
and diagnosing atopic allergies including asthma and related disorders

(57) This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor (2). One embodiment of the invention is a variant of AAF2, wherein deletion of

5-29 nucleotides in exon 5 is observed. The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.

HUMAN IL-9 RECEPTOR cDNA




FIG. 1

EP 1 471 144 A1

Description**CROSS-REFERENCE TO RELATED APPLICATION**

5 [0001] This application is related to U.S. Provisional Application Serial No. 60/032,224 which was filed December 2, 1996, and is incorporated by reference. It is also related to the subject matter of U.S. Patent Application Serial Nos. 08/697,419, 08/697,360, 08/697,473, 08/697,472, 08/697,471, 08/702,105, 08/702,110, 08/702,168 and 08/697,440 all of which were filed on August 23, 1996, and 08/874,503 filed on June 13, 1997, and are herein incorporated by reference.

10

FIELD OF THE INVENTION

15 [0002] This invention describes biologic variability in the IL-9 receptor (Asthma Associated Factor 2) (SEQ ID NO1) and relates these sequence variants to susceptibility to asthma, atopic allergy, and related disorders. This invention also teaches methods that utilize these IL-9 receptor sequence variants for the diagnosis of susceptibility or resistance to asthma and atopic allergy. In addition, methods are described that use variant IL-9 receptors in the development of pharmaceuticals for asthma which depend on the regulation of IL-9 activity.

20

BACKGROUND OF THE INVENTION

25

[0003] Inflammation is a complex process in which the body's defense system combats foreign entities. While the battle against foreign entities may be necessary for the body's survival, some defense systems improperly respond to foreign entities, even innocuous ones, as dangerous and thereby damage surrounding tissue in the ensuing battle.

30

[0004] Atopic allergy is a disorder where genetic background dictates the response to environmental stimuli. The disorder is generally characterized by an increased ability of lymphocytes to produce IgE antibodies in response to ubiquitous antigens. Activation of the immune system by these antigens also leads to allergic inflammation which may occur after their ingestion, penetration through the skin, or after inhalation. When this immune activation occurs and pulmonary inflammation ensues, this disorder is broadly characterized as asthma. Certain cells are important in this inflammatory reaction in the airways and they include T cells and antigen presenting cells, B cells that produce IgE, and mast cells/basophils that store inflammatory mediators and bind IgE, and eosinophils that release additional mediators. These inflammatory cells accumulate at the site of allergic inflammation, and the toxic products they release contribute to the tissue destruction related to the disorder.

35

[0005] While asthma is generally defined as an inflammatory disorder of the airways, clinical symptoms arise from intermittent airflow obstruction. It is a chronic, disabling disorder that appears to be increasing in prevalence and severity.¹ It is estimated that 30-40% of the population suffer with atopic allergy, and 15% of children and 5% of adults in the population suffer from asthma.¹ Thus, an enormous burden is placed on our health-care resources in the treatment of these disorders.

40

[0006] Both the diagnosis and treatment of asthma and related disorders are problematic.¹ In particular, the assessment of inflamed lung tissue is often difficult, and frequently the cause of the inflammation cannot be determined. Although atopic asthma is an ecogenetic disorder, knowledge about the particular variant genes has only recently been discovered. Methods to detect these genetic variations and their role in inflammation, diagnosis and prognosis remain to be determined. What is needed in the art is the development of technology to expedite the diagnosis of atopic asthma that specifically relates to variation in genes responsible for susceptibility/resistance to this atopic disease.

45

[0007] Current treatments suffer their own set of disadvantages. The main therapeutic agents, β -agonists, reduce the symptoms, i.e., transiently improve pulmonary functions, but do not affect the underlying inflammation so that lung tissue remains in jeopardy. In addition, constant use of β -agonists results in desensitization which reduces their efficacy and safety.² The agents that can diminish the underlying inflammation, the anti- inflammatory steroids, have their own known list of side effects that range from immunosuppression to bone loss.²

50

[0008] Because of the problems associated with conventional therapies, alternative treatment strategies have been evaluated.³⁸⁻³⁹ Glycophorin A,³⁷ cyclosporin,³⁸ and a nonapeptide fragment of IL-2,³⁶ all inhibit interleukin-2 dependent T lymphocyte proliferation.²⁸ They are, however, known to have many other effects.² For example, cyclosporin is used as an immunosuppressant after organ transplantation. While these agents may represent alternatives to steroids in the treatment of asthmatics,³⁶⁻³⁹ they inhibit interleukin-2 dependent T lymphocyte proliferation and potentially critical immune functions associated with homeostasis. What is needed in the art is technology to expedite the development of therapeutics that are specifically designed to treat the cause, and not the symptoms, of atopic asthma. These therapies represent the most likely way to avoid toxicity associated with nonspecific treatment. The therapies would selectively target a pathway, which is downstream from immune functions, such as IL-2 mediated T lymphocyte activation, that is necessary for the development of asthma and which would explain the episodic nature of the disorder and its close

association with allergy. Nature demonstrates that a pathway is the appropriate target for asthma therapy when biologic variability normally exists in the pathway and individuals demonstrating the variability are not immunocompromised or ill except for their symptoms of atopic asthma.

5 [0009] Because of the difficulties related to the diagnosis and treatment of atopic allergies including asthma, the complex pathophysiology of these disorders is under intensive study. While these disorders are heterogeneous and may be difficult to define because they can take many forms, certain features are found in common among asthmatics. Examples of such features include abnormal skin test response to allergen challenge, eosinophilia in the lung, bronchial hyperresponsiveness (BHR), bronchodilator reversibility, and airflow obstruction.³⁻¹⁰ These expressions of asthma related traits may be studied by quantitative or qualitative measures.

10 [0010] In many cases, elevated IgE levels are correlated with BHR, a heightened bronchoconstrictor response to a variety of stimuli.^{4,6,8,9} BHR is believed to reflect the presence of airway inflammation,^{6,8} and is considered a risk factor for asthma.¹¹⁻¹² BHR is accompanied by bronchial inflammation, including eosinophil infiltration into the lung and an allergic diathesis in asthmatic individuals.^{6,8,13-18}

15 [0011] A number of studies document a heritable component to atopic asthma.^{4,10} Family studies, however, have been difficult to interpret since these disorders are significantly influenced by age and gender, as well as many environmental factors such as allergens, viral infections, and pollutants.¹⁹⁻²¹ Moreover, because there is no known biochemical defect associated with susceptibility to these disorders, the mutant genes and their abnormal gene products can only be recognized by the anomalous phenotypes they produce.

20 [0012] The functions of IL-9 and the IL-9 receptor (the IL-9 pathway) now extend well beyond those originally recognized. While the IL-9 pathway serves as a stimulator of T cell growth, this cytokine is also known to mediate the growth of erythroid progenitors, B cells, mast cells, and fetal thymocytes.^{22,23} The IL-9 pathway acts synergistically with IL-3 in causing mast cell activation and proliferation.²⁴ The IL-9 pathway also potentiates the IL-4 induced production of IgE, IgG, and IgM by normal human B lymphocytes,²⁵ and the IL-4 induced release of IgE and IgG by murine B lymphocytes.²⁶ A role for the IL-9 pathway in the mucosal inflammatory response to parasitic infection has also been demonstrated.^{27,28}

25 [0013] Nevertheless, it is not known how the sequence of the IL-9 receptor specifically correlates with atopic asthma and bronchial hyperresponsiveness. It is known that IL-9 binds to a specific receptor expressed on the surface of target cells.^{23,29,30} The receptor actually consists of two protein chains: one protein chain, known as the IL-9 receptor, binds specifically with IL-9; the other protein chain is shared in common with the IL-2 receptor.²³ In addition, a cDNA encoding the human IL-9 receptor has been cloned and sequenced^{23,29,30} This cDNA codes for a 522 amino acid protein which exhibits significant homology to the murine IL-9 receptor. The extracellular region of the receptor is highly conserved, with 67% homology existing between the murine and human proteins. The cytoplasmic region of the receptor is less highly conserved. The human cytoplasmic domain is much larger than the corresponding region of the murine receptor.²³

30 [0014] The IL-9 receptor gene has also been characterized.³⁰ It is thought to exist as a single copy in the mouse genome and is composed of nine exons and eight introns.³⁰ The human genome contains at least four IL-9 receptor pseudogenes. The human IL-9 receptor gene has been mapped to the 320 kb subtelomeric region of the sex chromosomes X and Y.²³

35 [0015] In spite of these studies, no variants of the IL-9 receptor gene have been discovered. There is, therefore, a specific need for genetic information on atopic allergy, asthma, bronchial hyperresponsiveness, and for elucidation of the role of IL-9 receptor in the etiology of these disorders. This information can be used to diagnose atopic allergy and related disorders using methods that identify genetic variants of this gene that are associated with these disorders. Furthermore, there is a need for methods utilizing the IL-9 receptor variants to develop therapeutics to treat these disorders.

45 SUMMARY OF THE INVENTION

[0016] Applicants have discovered natural variants of the human IL-9 receptor (also known as Asthma Associated Factor 2 orAAF2) and have linked these variants to the pathogenesis of asthma and related disorders. These discoveries have led to the development of diagnostic methods, and methods to discover pharmaceuticals for the treatment of therapeutics for atopic asthma. In addition, applicants have determined that the IL-9 receptor is critical to a number of antigen-induced responses in mice, including bronchial hyperresponsiveness, eosinophilia and elevated cell counts in bronchial lavage, and elevated serum total IgE. These findings typify atopic asthma and the associated allergic inflammation.

50 [0017] Furthermore, applicants have determined that a G to A nucleic acid variant occurs at position 1273 of the cDNA (SEQ ID NO 2) which produces the predicted amino acid substitution of a histidine for an arginine at codon 344 of the human IL-9 receptor precursor protein. When the arginine residue occurs in both alleles in one individual, it is associated with less evidence of atopic asthma. Thus, applicants have identified the existence of a non-asthmatic

phenotype characterized by arginine at codon 344 when it occurs in both IL-9 receptor gene products in one individual. As an additional significant corollary, applicants have identified the existence of susceptibility to an asthmatic, atopic phenotype characterized by a histidine at codon 344. Thus, the invention includes purified and isolated DNA molecules having such a sequence as well as the proteins encoded by such DNA.

5 [0018] Applicants have also determined that a splice variant of the IL-9R exists wherein the glutamine residue at position 173 of the IL-9R precursor protein has been deleted (SEQ ID NO 3) (Figure 5). Applicants have further shown that this variant is not able to transcribe a signal through the Jak-Stat pathway (Figure 15) and is unable to induce cellular proliferation upon stimulation with IL-9 (Figure 16); therefore, individuals with this allele would be less susceptible to atopic asthma and related disorders.

10 [0019] Applicants have further determined that a variant of the IL-9R genomic DNA exists wherein nt-213, a thymine residue in intron 5 (213 nt upstream from exon 6), has been converted to a cytosine nucleotide. It is likely that such a variation can cause an increase in the frequency of the splice variant which removes the glutamine residue at the start of exon 6.

15 [0020] In addition, applicants have discovered a variant of IL-9R wherein exon 8 has been deleted (SEQ ID NO 4) which results in a change in reading frame and a premature stop codon in exon 9. Such a variant would most likely be prevented from transmitting a signal through the Jak-Stat pathway and, therefore, individuals with this allele would also be less susceptible to atopic asthma and related disorders.

20 [0021] The biological activity of IL-9 results from its binding to the IL-9 receptor and the consequent propagation of a regulatory signal in specific cells; therefore, IL-9 functions can be interrupted by the interaction of IL-9 antagonists with IL-9 or its receptor. Down regulation, i.e., reduction of the functions controlled by IL-9, is achieved in a number of ways. Administering antagonists that can interrupt the binding of IL-9 to its receptor is one key mechanism, and such antagonists are within the claimed invention. Examples include administration of polypeptide products encoded by the DNA sequences of a naturally occurring soluble form of the IL-9 receptor, wherein the DNA sequences code for a polypeptide comprising exons 2 and 3 (SEQ ID NO 5). Two other variations can produce soluble forms of the IL-9R receptor which comprise exons 2, 3 and 4 and in one case four amino acids from a different reading frame in exon 5 (SEQ ID NO 6) (Figure 6) and in the other case there are 27 amino acids from a different reading frame in exon 5 (SEQ ID NO 7) (Figure 7).

25 [0022] Methods to identify agonists and antagonists of the IL-9 receptor pathway can be identified by assessing receptor-ligand interactions which are well described in the literature. These methods can be adapted to high throughput automated assays that facilitate chemical screenings and potential therapeutic identification. Agonists are recognized by identifying a specific interaction with the IL-9 receptor. Loss of binding for a putative ligand which is labeled when a 100- to 1000-fold excess of unlabeled ligand is used is generally accepted as evidence of specific receptor binding. Many labels and detection schemes can be used during these experiments. A similar loss of binding when increasing concentrations of test compound are added to a known ligand and receptor is also evidence for an antagonist.

30 [0023] Knowledge of the variant receptors provides the means to construct expression vectors that can be used to make soluble receptor for receptor binding assays. Mutagenesis of these soluble receptors can be used to determine which amino acid residues are critical to bind ligand and aid in the structure-based design of antagonists.

35 [0024] Cells lacking human IL-9 receptor can be transiently or stably transfected with expression vectors containing a variant receptor and used to assay for IL-9 pathway activity. These activities may be cellular proliferation, or prevention of apoptosis which have both been ascribed to the IL-9 pathway. These cells can be used to identify receptor agonists and antagonists as described above.

40 [0025] The methods discussed above represent various effective methods utilizing the variant forms of IL-9 receptor to develop therapeutics for atopic asthma and other related disorders.

45 [0026] A number of techniques have been described that may be used to diagnose atopic asthma that recognize single nucleotide variants in the IL-9 receptor including DNA sequencing, restriction fragment length polymorphisms (RFLPs), allele specific oligonucleotide analyses (ASO), ligation chain reaction (LCR), chemical cleavage, and single stranded conformational polymorphism analyses (SSCP). A skilled artisan will recognize that the use of one or more of these techniques, as well as others in the literature, may be used to detect one or more variations in the IL-9 receptor gene or mRNA transcript and are within the scope of the present invention.

50 [0027] Still other techniques may be used to detect amino acid variants in the IL-9 receptor including ELISAs, immunoprecipitations, Westerns, and immunoblotting. Thus, polyclonal and monoclonal antibodies which recognize specifically the structure of the various forms of the IL-9 receptor are also within the scope of this invention and are useful diagnostic methods for describing susceptibility or resistance to atopic asthma and related disorders.

55 [0028] The methods discussed above represent various effective methods for diagnosing atopic asthma and other related disorders.

[0029] Thus, applicants have provided methods that use the IL-9 receptor to identify antagonists that are capable of regulating the interaction between IL-9 and its receptor. More specifically, applicants provide a method for assaying the functions of the IL-9 receptor to identify compounds or agents that may be administered in an amount sufficient to

down-regulate either the expression or functions of the IL-9 pathway.

[0030] Having identified the role of the IL-9 pathway in atopic allergy, bronchial hyperresponsiveness and asthma, applicants also provide a method for the diagnosis of susceptibility and resistance to atopic allergy, asthma, and related disorders.

[0031] The accompanying figures, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the invention and, together with the description, serve to explain the principle of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

[0032]

Figure 1: Schematic representation of the human IL receptor cDNA. Boxes depict exon 2 to 9 encompassing the coding region (relative size in scale, except the 3' untranslated part of exon 9, outlined by dashed line). Trans-membrane region is encoded by exon 7, intracellular domain by exon 8 and 9, and the extracellular by exon 2 to 6. Arrows indicate polymorphisms or aberrant splices affecting partial sequence of the exon; a) deletion of the first 5 or 29 nucleotides in exon 5; b) deletion of the first 3 nucleotides in exon 6 (codon 173); c) arg/gly polymorphism at codon 310; d) arg/his polymorphism at codon 344; e) polymorphism at codon 410+n consisting of either 8 or 9 serines; *) complete deletion of exon 3, 4 or 8.

Figure 2: Translated cDNA sequence of the wild type IL-9R precursor protein with Arg allele at codon 344 (nucleotides 1272-1274) and the 8 Ser/4 Asn repeats starting at codon 410 (nucleotides 1470-1472).

Figure 3: Translated cDNA sequence of the IL-9R precursor protein with the His allele at codon 344 (nucleotides 1272-1274) and the 9 Ser/4 Asn repeats starting at codon 410 (nucleotides 1470-1472).

Figure 4: Translated cDNA sequence of IL-9R precursor protein with the deletion of exon 8 causing a frame shift in exon 9, the production of 11 non-wild type amino acids and a premature stop codon.

Figure 5: Translated cDNA sequence of IL-9R precursor protein with the deletion of Glutamine at codon 173.

Figure 7: Translated cDNA sequence of IL-9R precursor protein with an alternate splice in exon 5 resulting in a premature stop codon and the production of 27 non-wild type amino acids.

Figure 6: Translated cDNA sequence of IL-9R precursor protein with an alternate splice in exon 5 resulting in a premature stop codon and the production of 4 non-wild type amino acids.

Figure 8: Translated cDNA sequence of IL-9R precursor protein with the deletion of exon 4 producing a stop codon as the first codon of exon 5.

Figure 9: Table showing the association between the IL-9 receptor genotype and atopic allergy. The Arg/Arg individuals are homozygous for the Arg allele with the 8 Ser/4 Asn repeats. The Arg/His individuals are heterozygous for the Arg allele with the 8 Ser/4 Asn repeats and the His allele with the 9 Ser/4 Asn repeats, 9 Ser/3 Asn repeats, and 10 Ser/2 Asn repeats in exon 9. The His/His individuals are homozygous for the His allele with the 9 Ser/4 Asn repeats, 9 Ser/3 Asn repeats, and 10 Ser/2 Asn repeats in exon 9. The Arg/Arg individuals are protected from atopic allergy. The Arg/His and His/His individuals are susceptible to atopic allergy ($P = 0.002$).

Figure 10: Map of the expression construct of the IL-9 receptor.

Figure 11: Western blot of recombinant IL-9 receptor proteins (left: Arg allele with the 8 Ser/4 Asn repeats; right: His allele with the 9 Ser/4 Asn repeats) using C terminal antibody probe in TK transfected cell line.

Figure 12: Expression of human IL-9 receptor variants in TS1 cells showing differential mobility between the Arg 344 variant with 8 Ser/4 Asn repeats (GR8) and His 344 variant with 9 ser/4 Asn repeats (GH9). A mobility shift is seen demonstrating differential post-translational modification of these two variant form of the IL-9 receptor.

Figure 13: XY specific amplimers for specific amplification of the IL-9 receptor gene. Pseudogenes on chromosomes 9, 10, 16, or 18 are not amplified by PCR. (M is mouse DNA, H is human DNA, and C is hamster DNA.)

Figure 14: Immunoreactivity of an anti-human IL-9 receptor neutralizing antibody with wild type and Delta-Q receptors. Panel A): COS7 cells were transiently transfected with the LXS vector alone (A and B), wild type IL-9R (C and D), Wild type IL-9R with 9 Ser residues starting with codon 410 (E and F), Δ -Q 173 variant (G and H) and Δ -Q 173 with 9 Ser residues starting at codon 410 (I and J) and sequentially incubated with MAB290 and anti-mouse IgG Texas Red-conjugated antibody (B,D,F,H and J) as described (Example 8). DAPI staining (A,C,E,G and I) was included to visualize every cell in the photographed field. Panel B): as in A) except that cells were first fixed/permabilized and then incubated with a C-terminal specific antibody (sc698) followed by incubation with anti-rabbit IgG Texas Red-conjugated antibody. Bar = 10 microns.

Figure 15: Activation of members of Jak, Stat, and Irs families via different variants of the human IL-9 receptor. TS1 cells expressing either GH9, Δ QGR8, or Δ QGH9 were starved for 6 hours and then treated for 5 minutes without cytokine (-), with murine IL-9 (m), or with human IL-9 (h). Cell extracts were immunoprecipitated with various antibodies specific for different members of Jak, Stat and Irs families. Immunoblots were first reacted with an anti-phosphotyrosine antibody to detect only tyrosine-phosphorylated proteins and then stripped and reprobed with

the same antibody used to immunoprecipitate each protein. GH9, ΔQGRB, ΔQGH9 are as indicated in Figure 16.

Figure 16: Proliferation of TS1 cells expressing different forms of human IL-9 receptor. Cells were seeded in quadruplicate in 96-well plates (1000/well) and treated without cytokine or with murine or human IL-9 (5 ng/ml). A colorimetric assay was performed 7 days later to determine cell number, and the ratio between treated/untreated cells (% control) was calculated to assess growth rate. LxSN = cells transfected with the empty vector; GR8 is wild type IL-9R; GH9 is the His 344 variant with 9 Ser residues starting at codon 410; ΔQGR8 and ΔQGH9 are the ΔQ173 variants on the wild type and the His 344 + 9 - Ser background, respectively.

Figure 17: Genomic DNA sequence of intron 5 of the IL-9R with a variation at nucleic acid 213 nt upstream from exon 6 where a T residue is changed to a C residue as indicated by the arrow.

DETAILED DESCRIPTION OF THE INVENTION

[0033] Applicants have resolved the needs in the art by elucidating an IL-9 pathway, and compositions that affect that pathway, which may be used in the treatment, diagnosis, and development of methods to identify agents to prevent or treat atopic asthma and related disorders.

[0034] Asthma encompasses inflammatory disorders of the airways with reversible airflow obstruction. Atopic allergy refers to atopy, and related disorders including asthma, bronchial hyperresponsiveness (BHR), rhinitis, urticaria, allergic inflammatory disorders of the bowel, and various forms of eczema. Atopy is a hypersensitivity to environmental allergens expressed as the elevation of serum total IgE or abnormal skin test responses to allergens as compared to controls. BHR refers to bronchial hyperresponsiveness, a heightened bronchoconstrictor response to a variety of stimuli.

[0035] By analyzing the DNA of individuals that exhibit atopic allergy and asthma-related disorders, applicants have identified polymorphisms in the IL-9 receptor (IL-9R) gene that may correlate with the expression of asthma. The IL-9 receptor gene (also known as Asthma Associated Factor 2 or AAF2) refers to the genetic locus of interleukin-9 receptor, a cytokine receptor associated with a variety of functions involving the regulation of human myeloid and lymphoid systems. The human IL-9 receptor gene of the present invention is found in the subtelomeric region of the XY chromosomes.

[0036] By polymorphism, applicants mean a change in a specific DNA sequence, termed a "locus," from the prevailing sequence. In general, a locus is defined as polymorphic when artisans have identified two or more alleles encompassing that locus and the least common allele exists at a frequency of 1% or more.

[0037] Specific amplification of the authentic IL-9R (gene encoding for the biologically functional protein located in the XYq pseudoautosomal region) using standard primer design was not possible because IL-9R has four highly homologous (>90% nucleotide identity), non-processed pseudogenes at other loci in the human genome (chromosome 9, 10, 16, 18). Because of the high identity of these other genes, genomic PCR amplification using standard primer design resulted in co-amplification of all genes, thus making sequence analysis of the authentic gene equivocal. In order to study authentic IL-9R structure as it may relate to predisposition to disease such as asthma, discussed in this application, or other diseases such as cancer (Renauld, et al., *Oncogene*, 9:1327-1332, 1994; Gruss, et al., *Cancer Res.*, 52:1026-1031, 1992), applicants have designed specific amplifiers. The specific primers were found to be authentic for IL-9R amplification with no amplification of the 4 pseudogenes. The primer sequences are shown in Example 2 and their specificity is demonstrated in Figure 13.

[0038] Applicants have also amplified, by RT-PCR, the entire coding region of the IL-9 receptor cDNA using RNA extracted from PBMCs (peripheral blood mononuclear cells) purified from 50 donors. Fig. 1 illustrates the most frequent variations found in 50 individuals analyzed. Exon 3, 4, 5, 6 and 8 were affected by aberrant splicing events in samples where full-length cDNAs could also be cloned. Some transcripts showed complete deletion of exon 3, which causes a frameshift creating a stop codon after a stretch of 79 unrelated residues. In the case of deletion of exon 4, a frameshift is also generated and the first codon in exon 5 is converted to a stop codon. In some other cDNAs, exon 5 presented partial deletion of the first 5 or 29 nucleotides, both deletions leading to frameshifts resulting in early stop codons within exon 5. Hence, in all instances, the putative truncated protein would lack most of the extracellular domain as well as all the transmembrane and cytoplasmic domains. If secreted, these forms might function as soluble receptors. Finally, the first three nucleotides of exon 6, corresponding to codon 173, were frequently found spliced out, resulting in deletion of the glutamine at this codon with no other changes in the remaining protein sequence. This splice variant is possibly related to a variant found in intron 5 of the genomic DNA (SEQ ID NO 24) which would increase the frequency of the splice variant (Figure 17 and Example 12).

[0039] Applicants have also found allelic variations limited to the coding sequence of exon 9. Polymorphisms involving codon 310 and 410 have been previously disclosed.^{29,30} (Kermouni, A., et al., *Genomics*, 371-382 (1995)). Codon 310 encodes for either arginine or glycine, depending on whether the first nucleotide at that codon is an adenine or a guanine, respectively. At codon 410 (from hereon termed "410+n") begins a stretch of either 8 or 9 AGC trinucleotides repeats which would be translated in 8 or 9 serines, respectively.

[0040] Applicants have found a new polymorphism at codon 344. Here, the second nucleotide is either adenine or guanidine, the two possible residues encoded by this codon being histidine or arginine, respectively. Moreover, a correspondence between codon 344 and 410+n was observed wherein arginine at codon 344 is consistently found with 8 serines at codon 410+n and histidine at codon 344 is found with 9 serines. The human IL-9 receptor cDNA originally cloned from a human megakaryoblastic leukemic cell line, Mo7e, presented 9 serines at codon 410+n and, unlike applicants' clones, an arginine at codon 344.²⁹ Another megakaryoblastic leukemic cell line UT-7 has been reported to carry the same arginine/9-serines allele.³⁰ Applicants cloned 16 cDNAs from Mo7e cell line and found that 6 had 8 serines at codon 410+n and arginine at codon 344. The remaining ten clones presented the published sequence. Applicants also genotyped the human acute myelogenous leukemia cell line KG-1 and found that it was histidine/9-serines homozygous.

[0041] These DNA molecules and corresponding RNA are isolated using techniques that are standard in the art, such as Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1985). By isolated, applicants mean that the DNA is free of at least some of the contaminants associated with the nucleic acid or polypeptides occurring in a natural environment.

[0042] The invention also includes the proteins encoded by these nucleic acid sequences. The invention further includes fragments of the molecules. By fragments, applicants mean portions of the nucleic acid sequence that maintain the function of the full sequence. As would be known in the art, fragments result from deletions, additions, substitutions and/or modifications.

[0043] The source of the IL-9 receptor variants of the invention is human. Alternatively, the DNA or fragment thereof may be synthesized using methods known in the art. It is also possible to produce the compound by genetic engineering techniques, by constructing DNA by any accepted technique, cloning the DNA in an expression vehicle and transfecting the vehicle into a cell which will express the compound. See, for example, the methods set forth in Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1985).

[0044] The demonstration of variant IL-9 receptor sequences which may be associated with atopic allergy and an asthma-like phenotype, and others which may be associated with the lack of an asthma-like phenotype, provides methods of diagnosing susceptibility to atopic asthma and related disorders. Certain variants can produce soluble receptors which can be used for treating these disorders.

[0045] A receptor is a soluble or membrane-bound component that recognizes and binds to molecules, and the IL-9 receptor of the invention is the component that recognizes and binds to IL-9. The functions of the IL-9 receptor consist of binding to IL-9 or an IL-9-like molecule and propagating its regulatory signal in specific cells.^{29,30,34,35} Human IL-9 has been shown to cause phosphorylation of the IL-9 receptor itself and the activation of proteins of the Jak-Stat pathway, Jak1, Stat1, Stat3, Stat5, and Irs2, upon binding the human IL-9 receptor (Demoulin, J-B., et al., Molecular and Cellular Biology, p. 4710-4716, Sept. 1996). Applicants have examined whether IL-9R or its variants showed any bias in the activation of these proteins and extended the analysis to Jak3 and Irs1. It was determined that all of the proteins of the pathway including Jak3 and Irs1 were phosphorylated by IL-9R activation. It was also determined that IL-9R variants with changes at codons 310, 344 and 410+n provided the same up-regulation as wild type IL-9R. Therefore, one aspect of the invention is therapeutics for the treatment of atopic asthma which inhibit interactions in the Jak-Stat pathway.

[0046] Unlike the wild type receptor and the other tested variants, the ΔQ173 variant could not activate any proteins in the Jak-Stat pathway (Figure 15). In addition, the ΔQ173 variant could not support cellular proliferation upon IL-9 stimulation (Figure 16). Therefore, individuals who express the ΔQ173 variant are less likely to be susceptible to atopic asthma and related disorders. One aspect of the invention, therefore, is therapeutics that increase the expression of the ΔQ173 splice variant for the treatment of atopic asthma and related disorders.

[0047] One diagnostic embodiment involves the recognition of variations in the DNA sequence of the IL-9 receptor gene or transcript. One method involves the use of a nucleic acid molecule (also known as a probe) having a sequence complementary to the IL-9 receptors of the invention under sufficient hybridizing conditions, as would be understood by those in the art. In one embodiment, the nucleic acid molecule will bind specifically to the codon for Arg344 of the mature IL-9 receptor protein, or to His344, and in another embodiment will bind to both Arg344 and to His344. In yet another embodiment, it will bind to the codon for Gln 173. These methods may also be used to recognize other variants of the IL-9 receptor. Another method of recognizing DNA sequence variation associated with these disorders is direct DNA sequence analysis by multiple methods well known in the art.⁴⁴ Another embodiment involves the detection of DNA sequence variation in the IL-9 receptor gene associated with these disorders.⁴⁰⁻⁴⁴ These include the polymerase chain reaction, restriction fragment length polymorphism (RFLP) analysis, and single-stranded conformational analysis. In a preferred embodiment, applicants provide specifically for a method to recognize, on a genetic level, the polymorphism in IL-9 receptor associated with the His344 and Arg344 alleles using an ASO PCR. In other embodiments, the ligation chain reaction can be used to distinguish these alleles of IL-9 receptor genes.

[0048] The present invention also includes methods for the identification of antagonists of IL-9 and its receptor. Antagonists are compounds that are themselves devoid of pharmacological activity, but cause effects by preventing

the action of an agonist. To identify an antagonist of the invention, one may test for competitive binding with a known agonist or for down-regulation of IL-9-like functions as described herein and in the cited literature.^{2,22-35}

[0049] Specific assays may be used to screen for pharmaceuticals useful in treating atopic allergy based on IL-9 receptor's known role on the proliferation of T lymphocytes, IgE synthesis and release from mast cells.^{29,30,33-35} Another assay involves the ability of human IL-9 receptor to specifically induce the rapid and transient tyrosine phosphorylation of multiple proteins in Mo7e cells.³⁴ Because this response is dependent upon the expression and activation of the IL-9 receptor, it represents a simple method or assay for the characterization of potentially valuable compounds. The tyrosine phosphorylation of Stat3 transcriptional factor appears to be specifically related to the functions of the IL-9 receptor,³⁵ and this response represents a simple method or assay for the characterization of compounds within the invention. Still another method to characterize the function of the IL-9 receptor involves the use of the well known murine TS1 clone transfected with a human receptor which can be used to assess human IL-9 function with a cellular proliferation assay.²⁹ These methods can be used to identify antagonists of the IL-9 receptor.

[0050] In a further embodiment, the invention includes the down-regulation of IL-9 expression or function by administering soluble IL-9 receptor molecules that bind IL-9. Applicants and Renauld, et al.²⁹ have shown the existence of a soluble form of the IL-9 receptor. This molecule can be used to prevent the binding of IL-9 to cell-bound receptor and act as an antagonist of IL-9. Soluble receptors have been used to bind cytokines or other ligands to regulate their function.⁴⁵ A soluble receptor is a form of a membrane-bound receptor that occurs in solution, or outside of the membrane. Soluble receptors may occur because the segment of the molecule which commonly associates with the membrane is absent. This segment is commonly referred to in the art as the transmembrane domain of the gene, or membrane-binding segment of the protein. Thus, in one embodiment of the invention, a soluble receptor may represent a fragment or an analog of a membrane-bound receptor.

[0051] Applicants have identified three splice variants of the human IL-9 receptor that result in the production of proteins that could act as soluble receptors. One splice variant resulted in the deletion of exon 4 which introduced a frameshift resulting in a stop codon as the first codon of exon 5. This variant would produce a peptide of about 45 residues that contains an epitope reactive with antibodies that block the IL-9/IL-9R interaction. The other two variants contain deletions in exon 5 that will produce premature stop codons early in the exon, but, in these cases, without the deletion of exon 4. These variants would produce a protein of about 100 residues also containing the epitope recognized by blocking antibody.

[0052] Soluble IL-9 receptors may be used to screen for potential therapeutics, including antagonist useful in treating atopic asthma and related disorders. For example, screening for peptides and single-chain antibodies using phage display could be facilitated using a soluble receptor. Phage that bind to the soluble receptor can be isolated and the molecule identified by affinity capture of the receptor and bound phage. In addition, compound screenings for agents useful in treating atopic asthma and related disorders can incorporate a soluble receptor and ligand that bind in the absence of an antagonist. Detection of the ligand and receptor interaction occurs because of the proximity of these molecules. Antagonists are recognized by inhibiting these interactions.

[0053] In addition, the invention includes pharmaceutical compositions comprising the compounds of the invention together with a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectionable solutions. Suitable pharmaceutical carriers are described in Martin, E.W., Remington's Pharmaceutical Sciences, specifically incorporated herein by reference.

[0054] The compounds used in the method of treatment of this invention may be administered systemically or topically, depending on such considerations as the condition to be treated, need for site-specific treatment, quantity of drug to be administered, and similar considerations.

[0055] Topical administration may be used. Any common topical formation such as a solution, suspension, gel, ointment, or salve and the like may be employed. Preparation of such topical formulations are well described in the art of pharmaceutical formulations as exemplified, for example, by Remington's Pharmaceutical Science, Edition 17, Mack Publishing Company, Easton, Pa. For topical application, these compounds could also be administered as a powder or spray, particularly in aerosol form. In a preferred embodiment, the compounds of this invention may be administered by inhalation. For inhalation therapy, the compound may be in a solution useful for administration by metered dose inhalers, or in a form suitable for a dry powder inhaler.

[0056] The active ingredient may be administered in pharmaceutical compositions adapted for systemic administration. As is known, if a drug is to be administered systemically, it may be confectioned as a powder, pill, tablet or the like, or as a syrup or elixir for oral administration. For intravenous, intraperitoneal or intralesional administration, the compound will be prepared as a solution or suspension capable of being administered by injection. In certain cases, it may be useful to formulate these compounds in suppository form or as an extended release formulation for deposit under the skin or intermuscular injection.

[0057] An effective amount is that amount which will down-regulate the functions controlled by IL-9 receptor. A given effective amount will vary from condition to condition and in certain instances may vary with the severity of the condition being treated and the patient's susceptibility to treatment. Accordingly, a given effective amount will be best determined at the time and place through routine experimentation. It is anticipated, however, that in the treatment of asthma and related disorders in accordance with the present invention, a formulation containing between 0.001 and 5 percent by weight, preferably about 0.01 to 1%, will usually constitute a therapeutically effective amount. When administered systemically, an amount between 0.01 and 100 mg per kg body weight per day, but preferably about 0.1 to 10 mg/kg, will affect a therapeutic result in most instances.

[0058] Applicants also provide for a method to screen for the compounds that down-regulate the functions controlled by the IL-9 receptor. One may determine whether the functions expressed by IL-9 receptor are down-regulated using techniques standard in the art.^{29,30,34,35} In a specific embodiment, applicants provide for a method of identifying compounds with functions comparable to IL-9. In one embodiment, the functions of IL-9 receptor may be assessed *in vitro*. As is known to those in the art, human IL-9 receptor activation specifically induces the rapid and transient tyrosine phosphorylation of multiple proteins in cells responsive to IL-9. The tyrosine phosphorylation of Stat3 transcriptional factor appears to be specifically related to the actions of the IL-9 pathway. Another method to characterize the function of IL-9 and IL-9-like molecules depends on the "stable expression" of the IL-9 receptors in murine TS1 clones or TF1 clones, which do not normally express human receptor. These transfectants can be used to assess human IL-9 receptor function with a cellular proliferation assay.²⁹

[0059] The invention also includes a simple screening assay for saturable and specific ligand binding based on cell lines that express the IL-9 receptor variants.^{23,29} The IL-9 receptor is expressed in a wide variety of cell types, including K562, C8166-45, KG-1 transfected with the human IL-9 receptors, B cells, T cells, mast cells, HL60, HL60-clone 5, TS1 transfected with the human IL-9 receptors, 32D transfected with the human IL-9 receptors, neutrophils, megakaryocytes (UT-7 cells),³⁰ the human megakaryoblastic leukemia cell line Mo7e³⁴, TF1,²⁹ macrophages, eosinophiles, fetal thymocytes, the human kidney cell line 293,³⁰ and murine 32D and embryonic hippocampal progenitor cell lines.^{23,29,30}

[0060] The practice of the present invention will employ the conventional terms and techniques of molecular biology, pharmacology, immunology, and biochemistry that are within the ordinary skill of those in the art. See, for example, Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, or Ausubel, et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc.

[0061] Nonetheless, we offer the following basic background information. The body's genetic material, or DNA, is arranged on 46 chromosomes, which each comprises two arms joined by a centromere. Each chromosome is divided into segments designated p or q. The symbol p is used to identify the short arm of a chromosome, as measured from the centromere to the nearest telomere. The long arm of a chromosome is designated by the symbol q. Location on a chromosome is provided by the chromosome's number (i.e., chromosome 5) as well as the coordinates of the p or q region (i.e., q31-q33). In addition, the body bears the sex chromosomes, X and Y. During meiosis, the X and Y chromosomes exchange DNA sequence information in areas known as the pseudoautosomal regions.

[0062] DNA, deoxyribonucleic acid, consists of two complementary strands of nucleotides, which include the four different base compounds, adenine (A), thymine (T), cytosine (C), and guanine (G). A of one strand bonds with T of the other strand while C of one strand bonds to G of the other to form complementary "base pairs," each pair having one base in each strand.

[0063] A sequential grouping of three nucleotides (a "codon") codes for one amino acid. Thus, for example, the three nucleotides CAG code for the amino acid Glutamine. The 20 naturally occurring amino acids, and their one-letter codes, are as follows:

45	Alanine	Ala	A
	Arginine	Arg	R
	Asparagine	Asn	N
	Aspartic Acid	Asp	D
	Asparagine or Aspartic acid	Asx	B
50	Cysteine	Cys	C
	Glutamine	Gln	Q
	Glutamine Acid	Glu	E
	Glutamine or Glutamic acid	Glx	Z
	Glycine	Gly	G
	Histidine	His	H
55	Isoleucine	Ile	I
	Leucine	Leu	L

(continued)

Lysine	Lys	K
Methionine	Met	M
Phenylalanine	Phe	F
Proline	Pro	P
Serine	Ser	S
Threonine	Thr	T
Tryptophan	Trp	W
Tyrosine	Tyr	Y
Valine	Val	V

5

10

20

[0064] Amino acids comprise proteins. Amino acids may be hydrophilic, i.e., displaying an affinity for water, or hydrophobic, i.e., having an aversion to water. Thus, the amino acids designated as G, A, V, L, I, P, F, Y, W, C and M are hydrophobic and the amino acids designated as S, Q, K, R, H, D, E, N and T are hydrophilic. In general, the hydrophilic or hydrophobic nature of amino acids affects the folding of a peptide chain and, consequently, the three-dimensional structure of a protein.

[0065] DNA is related to protein as follows:

25

genomic DNA ---> mRNA ---> protein

↓
cDNA

30

Genomic DNA comprises all the DNA sequences found in an organism's cell. It is "transcribed" into messenger RNA ("mRNA"). Complementary DNA ("cDNA") is a complementary copy of mRNA made by reverse transcription of mRNA. Unlike genomic DNA, both mRNA and cDNA contain only the protein-encoding or polypeptide-encoding regions of the DNA, the so-called "exons." Genomic DNA may also include "introns," which do not encode proteins.

35

[0066] In fact, eukaryotic genes are discontinuous with proteins encoded by them, consisting of exons interrupted by introns. After transcription into RNA, the introns are removed by splicing to generate the mature messenger RNA (mRNA). The splice points between exons are typically determined by consensus sequences that act as signals for the splicing process. Splicing consists of a deletion of the intron from the primary RNA transcript and a joining or fusion of the ends of the remaining RNA on either side of the excised intron. Presence or absence of introns, the composition of introns, and number of introns per gene, may vary among strains of the same species, and among species having the same basic functional gene. Although, in most cases, introns are assumed to be nonessential and benign, their categorization is not absolute. For example, an intron of one gene can represent an exon of another. In some cases, alternate or different patterns of splicing can generate different proteins from the same single stretch of DNA. In fact, structural features of introns and the underlying splicing mechanisms form the basis for classification of different kinds of introns.

40

[0067] As to the exons, these can correspond to discrete domains or motifs as, for example, functional domains, folding regions, or structural elements of a protein; or to short polypeptide sequences, such as reverse turns, loops, glycosylation signals and other signal sequences, or unstructured polypeptide linker regions. The exon modules of the present combinatorial method can comprise nucleic acid sequences corresponding to naturally occurring exon sequences or naturally occurring exon sequences which have been mutated (e.g., point mutations, truncations, fusions).

45

[0068] Returning now to the manipulation of DNA, DNA can be cut, spliced, and otherwise manipulated using "restriction enzymes" that cut DNA at certain known sites and DNA ligases that join DNA. Such techniques are well known to those of ordinary skill in the art, as set forth in texts such as Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1985) or Ausubel, et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (1994).

50

[0069] DNA of a specific size and sequence can then be inserted into a "replicon," which is any genetic element, such as a plasmid, cosmid, or virus, that is capable of replication under its own control. A "recombinant vector" or "expression vector" is a replicon into which a DNA segment is inserted so as to allow for expression of the DNA; i.e., production of the protein encoded by the DNA. Expression vectors may be constructed in the laboratory, obtained from

other laboratories, or purchased from commercial sources.

[0070] The recombinant vector (known by various terms in the art) may be introduced into a host by a process generically known as "transformation." Transformation means the transfer of an exogenous DNA segment by any of a number of methods, including infection, direct uptake, transduction, F-mating, microinjection, or electroporation into a host cell.

[0071] Unicellular host cells, known variously as recombinant host cells, cells, and cell culture, include bacteria, yeast, insect cells, plant cells, mammalian cells and human cells. In particularly preferred embodiments, the host cells include *E.coli*, *Pseudomonas*, *Bacillus*, *Streptomyces*, Yeast, CHO, R1-1, B-W, LH, COS-J, COS-7, BSC1, BSC40, BMT10, and S69 cells. Yeast cells especially include *Saccharomyces*, *Pichia*, *Candida*, *Hansenula*, and *Torulopsis*.

[0072] As those skilled in the art recognize, the expression of the DNA segment by the host cell requires the appropriate regulatory sequences or elements. The regulatory sequences vary according to the host cell employed, but include, for example, in prokaryotes, a promoter, ribosomal binding site, and/or a transcription termination site. In eukaryotes, such regulatory sequences include a promoter and/or a transcription termination site. As those in the art well recognize, expression of the polypeptide may be enhanced, i.e., increased over the standard levels, by careful selection and placement of these regulatory sequences.

[0073] In other embodiments, promoters that may be used include the human cytomegalovirus (CMV) promoter, tetracycline-inducible promoter, simian virus (SV40) promoter, moloney murine leukemia virus long terminal repeat (LTR) promoter, glucocorticoid inducible murine mammary tumor virus (MMTV) promoter, herpes thymidine kinase promoter, murine and human-actin promoters, HTLV1 and HIV IL-9 5' flanking region, human and mouse IL-9 receptor 5' flanking region, bacterial tac promoter and *Drosophila* heat shock protein scaffold attachment region (SAR) enhancer elements.

[0074] The DNA may be expressed as a polypeptide of any length such as peptides, oligopeptides, and proteins. Polypeptides also include translational modifications such as glycosylations, acetylations, phosphorylations, and the like.

[0075] Another molecular biologic technique of interest to the present invention is "linkage analysis." Linkage analysis is an analytic method used to identify the chromosome or chromosomal region that correlates with a trait or disorder.⁴⁷ Chromosomes are the basic units of inheritance on which genes are organized. In addition to genes, artisans have identified "DNA markers" on chromosomes. DNA markers are known sequences of DNA whose identity and sequence can be readily determined. Linkage analysis methodology has been applied to the mapping of disease genes, for example, genes relating to susceptibility to asthma, to specific chromosomes.^{47,48}

[0076] Applicants wish to incorporate by reference all the references set forth above and below.

[0077] Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed. It is intended that the specification and examples be considered exemplary only with a true scope of the invention being indicated by the claims.

[0078] Having provided this background information, applicants now describe preferred aspects of the invention.

EXAMPLE 1

Identification of IL-9 receptor transcript polymorphisms

[0079] A population of 52 individuals was ascertained randomly with respect to asthma and atopy from the Philadelphia, Pennsylvania, area. Total serum IgE were assayed by enzyme-linked immunosorbent assay (ELISA, Genzyme, Cambridge, Massachusetts).

[0080] To assess the structural forms of the human IL-9 receptor cDNA, PBMCs from these 52 unrelated donors were isolated and cultured in the presence of PHA and PMA (described in Example 4). Previous data from applicants' laboratory demonstrated the kinetics of expression for IL-9 receptor message in primary cultures peak at day 6 after mitogen stimulation. Applicants cultured the cells, therefore, for 6 days at which time the cells were harvested and their RNA and DNA were isolated as described in Example 5.

[0081] RNAs were reverse transcribed and amplified by PCR using primers specific for full-length IL-9 receptor cDNA as described in Example 5. Amplification products from each individual were cloned into the TA PCR cloning vector and ten clones containing the expected inserts (as determined by digestion and gel electrophoresis) were sequenced in their entirety and analyzed for structural or sequence variation.

[0082] Seven major variants were identified from the above screen. These cDNAs represent a codon 173 deletion, an exon 4 deletion, two separate deletions in exon 5, an exon 8 deletion, and a full-length cDNA containing an ARG-to-HIS change at codon 344 of the mature protein. Additional variants exist on each of these genetic backgrounds. The Arg allele is associated with 8 Ser/4 Asn repeats and 7 Ser/4 Asn repeats; the His allele is associated with 9 Ser/4 Asn repeats, 9 Ser/3 Asn repeats, and 10 Ser/2 Asn. All of these variants are depicted in Figure 1.

[0083] Variants were cloned into the eukaryotic expression vector pCEP4 (Clontech) which contains a CMV promoter

that drives the expression of the cloned cDNA followed by an SV40 polyadenylation signal. The vector also contains a hygromycin B resistance gene which is used for selection of eukaryotic cells containing the vector and presumably expressing the cloned cDNA under control of the CMV promoter. Recombinant plasmids were analyzed by sequence and those plasmids containing the correct cDNA inserts were transfected into eukaryotic recipient cells such as the
 5 Syrian hamster fibroblast TK-ts13, the human glioblastoma T98G, the human myeloid leukemia line TF-1, and the murine myeloid precursor cell line 32D as described in Example 3. Function was biologically assessed as a response to the IL-9 ligand in growth and/or apoptosis (Examples 7 and 10).

[0084] Experiments in which the full-length IL-9 receptor cDNAs containing the ARG or HIS variants were performed are the TK-ts13 hamster fibroblasts or the human T98G glioblastoma cells. Cells were transfected and analyzed 48
 10 hours later by Western blot and *in situ* staining using human specific carboxy terminal antibodies (Santa Cruz) (Example 8). *In situ* analysis demonstrated that both forms of receptor appeared to be expressed in both the hamster and human lines (Figures 11 and 12). Interestingly, while Western blots of both forms appeared to be expressed at equal levels in both the human and hamster lines, a differential migration pattern appeared between the ARG and HIS receptor forms
 15 in the TS1 cell line (Figure 12) which suggests a differential post-translational modification such as glycosylation, phosphorylation, etc. This biochemical difference may be the mechanism by which the altered function results in altered phenotype.

[0085] The frequency of the various substitutions were used as an unbiased estimate of the prevalence of each variant in the general population. Genotype was compared to phenotype assessed by questionnaire. A diagnosis of allergy and asthma was determined by a physician reviewing the questionnaires. Individuals homozygous for the
 20 Arg344 alleles were significantly less likely to demonstrate evidence for allergy and asthma when compared to heterozygotes or homozygous His344 (Figure 9).

EXAMPLE 2

25 Genomic analysis of the IL-9 receptor genes.

[0086] In order to perform genomic analyses of allergic and/or asthmatic individuals, the following strategy was designed to create PCR-specific primers for the authentic IL-9 receptor genes located on the X/Y pseudoautosomal regions and exclude the highly conserved IL-9 receptor pseudogenes located on chromosomes 9,10,16, and 18. First,
 30 sequence alignments were preformed between the two published pseudogenes and the genomic sequence of the IL-9 receptor genes. Primers were then initially designed in divergent regions between the authentic genes and the pseudogenes, and then analyzed by PCR using single chromosome-specific hybrids derived from Corell DNA Repository (Camden, NJ). If the primers only produce correct sized products from X and Y hybrids, they were then optimized for robust amplification. In several cases, primers directed to the divergent regions were not XY specific; therefore, applicants introduced additional base changes in the particular primer to increase the number of mismatches higher against the pseudogenes as compared to the IL-9 receptor gene sequence. Table 1 contains the sequence of the primers and optimal annealing temperatures for XY-specific amplification. The specificity of these primers for XY amplification are demonstrated in Figure 13.

40

45

50

55

Table 1: X/Y Specific Amplimers of IL-9 Receptor

EXON	SENSE PRIMER	ANTISENSE PRIMER	TEMP	SIZE
2	5'- GCA GGT GGG GAC CCA TG -3' (SEQ ID NO 8)	5'- AGG CTT GAC ATC GGA CAA C -3' (SEQ ID NO 9)	68°	300 bp
3	5'- CTG GCC TGA AGT ACT TAC C -3' (SEQ ID NO 10)	5'- CTG CTT CAA TCC TGG GGA A -3'(SEQ ID NO 11)	62°	222 bp
4	5'- GTG AGT TCC CCA GGA TTG A -3' (SEQ ID NO 12)	5'- CAA GGC CCT GCT CCA AA -3' (SEQ ID NO 13)	64°	335 bp
5	5'- TGG GGC TTC AGC CTC ACA TG -3' (SEQ ID NO 14)	5'- TAT GTA GAG TGG GGA GTC TA -3' (SEQ ID NO 15)	62°	259 bp
6	5'- TGT ATT CTC GAG GGC TGA G -3' (SEQ ID NO 16)	5'- TGA GGT GAA CAG GGG AGA A -3' (SEQ ID NO 17)	62°	337 bp
7	5'- CCC TGG GCC CTT CAT GT -3' (SEQ ID NO 18)	5'- ACA AGG GCG GCC TTT GAT -3' (SEQ ID NO 19)	60°	262 bp
8	5'- AGG GAC GAG GTG GGC GGA C -3' (SEQ ID NO 20)	5'- CCT GCC CCC CAT GTT CTT -3' (SEQ ID NO 21)	58°	376 bp
9	5'- ATG CTA CCT GAG CCC TTC C -3' (SEQ ID NO 22)	5'- GGA CAT GAT GCA TCT GGC G -3' (SEQ ID NO 23)	62°	664 bp

These primers represent a novel method for analyzing DNA sequence variation in these genes which can be used for diagnosis of susceptibility or resistance to atopic asthma and related disorders.

[0087] Using this technology, each exon was examined by DNA sequence analyses for individuals in applicants' populations to detect sequence variation in the IL-9 receptor gene.⁴⁴ Sequence polymorphisms were distinguished from artifact by repeated analyses. An association of the receptor variants with the allergic phenotypes is set forth in Figure 9. The sequence of the receptor alleles is set forth in Figures 1-8.

EXAMPLE 3

IL-9 receptor expression and ligand binding assay

[0088] Purified recombinant IL-9 and compounds potentially resembling IL-9 in structure or function are fluorescently labeled to high specific activity by using commercially available techniques according to the supplier's recommendations (Pierce). Human Mo7e and murine 32D cells are grown and resuspended at 37°C in 0.8ml of Dulbecco's modified Eagle's medium supplemented with 10% (vol/vol) fetal bovine serum, 50 mM 2-mercaptoethanol, 0.55 mM L-arginine, 0.24 mM L-asparagine, and 1.25 mM L-glutamine or RPMI supplemented with 10% (vol/vol) fetal bovine serum, 50 mM 2-mercaptoethanol, 0.55 mM L-arginine, 0.24 mM L-asparagine, and 1.25 mM L-glutamine, respectively. TF1.1 (TF1 cells lacking human IL-9 receptors), T98G, TK⁻, and murine 32D cells, (Examples 7 and 10) were used as is or after transfection with the human IL-9 receptor constructs as described below. Plasmid DNA containing one of the full-length or truncated forms of IL-9 receptors were cloned into pCEP4 plasmid (Clontech) and purified by centrifugation through Qiagen columns (Qiagen). Plasmid DNA (50 micrograms) was added to the cells in 0.4 cm cuvettes just before electroporation. After a double electric pulse (750V/74 ohms/40 microfarads and 100 V/74 ohms/2100 microfarads), the cells are immediately diluted in fresh medium supplemented with IL-9.

[0089] Stable transfected cells were generated after 14 days of selection with hygromycin B (400 µg/ml to 1.6 mg/

ml). Hygromycin-resistant clones were analyzed for IL-9 receptor expression by Western blots and *in situ* staining as described in Example 8.

[0090] Cellular receptor binding is visualized directly in real time with fluorescence microscopy. Binding and internalization is followed over time in control cells (not transfected), and with cells transfected with each of the known IL-9 receptor variants. An excess of unlabeled ligand or blocking antibody is used in parallel experiments to demonstrate specific binding.

[0091] Soluble IL-9 receptor including amino acids 44 to 270 with or without a HA ditag is also incubated with different forms of human labeled recombinant IL-9. Varying amounts of FLAG-tagged (IBI) ligand are incubated in PBS at room temperature for 30 minutes with 0.5 µg of soluble receptor. EBC buffer (50 mM Tris pH 7.5; 0.1 M NaCl; 0.5% NP40) is added (300 µl) along with 1 µg of anti-HA antibody or anti-FLAG monoclonal antibody (IBI) and incubated for 1 hour on ice. Forty microliters of protein A sepharose solution were added to each sample and mixed for 1 hour at 4°C. Samples were centrifuged for 1 minute 11,000 X G and pellets were washed 4 times with 500 µl of EBC. Pellets were dissolved in 26 µl of 2X SDS buffer, boiled for 4 minutes, and electrophoresed through an 18% SDS polyacrylamide gel. Western blots were probed with an anti-IL-9 receptor antibody (Santa Cruz Inc.) or anti-FLAG monoclonal antibody (IBI) against FLAG-tagged rhIL-9. Therapeutic candidates are assessed by measuring the antagonism of ligand binding. Receptor expression is shown in Figures 11 and 14.

EXAMPLE 4

Cell Isolation and culture

[0092] Human peripheral blood mononuclear cells (PBMC) were isolated from healthy donors by density gradient centrifugation using endotoxin tested Ficoll-Paque PLUS according to the manufacturer (Pharmacia Biotech, AB Uppsala Sweden). PBMC (5×10^6), mouse spleen cells (5×10^6), or 5×10^6 Mo7e cells were cultured in 7 ml of RPMI-1640 (Bethesda Research Labs (BRL), Bethesda, MD) supplemented to a final concentration of 10% with either isogenic human serum or heat-inactivated FBS. Cells were cultured for 24 hrs at 37°C either unstimulated, or stimulated with either PMA 5 µg/ml/ PHA 5 µg/ml, or PHA 5 µg/ml and rhIL2 50 ng/ml (R&D Systems, Minneapolis, MN).

EXAMPLE 5

DNA & RNA isolations, rtPCR, cloning, and sequencing of PCR products

[0093] Cytoplasmic RNA and genomic DNA were extracted after 6 days of mitogen stimulation from cultured PBMCs, as described by Nicolaides and Stoeckert.⁴⁶ One µg of RNA from each source was denatured for >10 minutes at 70°C and then reverse transcribed(V+) into cDNA using 2.5 units of Superscript II reverse transcriptase (GIBCO, BRL), 1U/ µg RNAse Inhibitor, 2.5 mM oligo d(T)16 primer, 1 mM each of dATP, dCTP, dGTP, dTTP, 50 mM KCl, 10 mM Tris-HCL, pH 7.0, 25 mM MgCl₂ at 37°C for one hour. A mock reverse transcription reaction was used as a negative control.

[0094] One-twentieth of the rt reaction was used in PCR (50 µl) containing 6.7 mM MgCl₂, 16.6 mM (NH₄)₂SO₄, 67 mM Tris-HCl, pH 8.8, 10 mM 2-mercaptoethanol, 6% DMSO, 1.25 mM of each dNTP, 2.5U Amplitaq DNA polymerase, and 300 ng of each of the oligonucleotides representing human cDNA IL-9 exon 2 (forward 5'-GCT GGA CCT TGG AGA GTG-3')(SEQ ID NO 1) and exon 9 (reverse 5'-GTC TCA GAC AAG GGC TCC AG-3')(SEQ ID NO 2). The reaction mixture was subjected to the following PCR conditions: 120 seconds at 95°C, then 35 cycles at: 30 seconds at 94°C; 90 seconds at 58°C; 90 seconds at 72°C. Finally, the reaction mixture was cycled one time for 15 minutes at 72°C for extension.

[0095] PCR products representing hIL-9 receptor cDNA were subjected to gel electrophoresis through 1.5% agarose gels and visualized using ethidium bromide staining. Products of a mock reverse transcriptase reaction, in which H₂O was substituted for RNA, were used as a negative control amplification in all experiments.

[0096] PCR products were subcloned into the TA Cloning vector (Invitrogen, San Diego, CA). Amplification of the human cDNA gave a 1614 bp product. Plasmids containing hIL-9 receptor cDNA inserts were isolated by conventional techniques (Sambrook, J., et al. (1989) Molecular Cloning: A Laboratory Manual Cold Spring Harbor Laboratory Press, New York). After amplification the DNA sequence including and surrounding each insert was analyzed by sequencing (Sanger et al., 1977, Proc. Natl. Acad. Sci. USA 74:5463) using fluorescent dideoxyterminators and on an automated sequencer (ABI 377, Perkin Elmer) for determination of PCR-induced or cloning-induced errors. hIL-9 receptor cDNA inserts without cloning and/or polymerase-induced sequence errors were subcloned into expression vectors.

EXAMPLE 6

Cloning and expression of IL-9 receptor constructs *in vitro*

5 [0097] hIL-9 receptors were subcloned into the episomal eukaryotic expression vector pCEP4 (Clontech). Inserts were cloned as BamH1-Xhol fragments into the pCEP4 polylinker in the sense orientation to the CMV promoter using standard techniques (Figure 10). Constructs were expressed in cellular hosts as described.

EXAMPLE 7

10 Cellular assays using (Mo7e, 32D, TF1.1, TK-ts13, and T98G)

15 [0098] Cell lines were used to assess the function of variant IL-9 receptors and for the screening of compounds potentially useful in the treatment of atopic asthma. Compounds were tested for their ability to antagonize the anti-apoptotic or baseline proliferative response elicited by IL-9. Once a baseline anti-apoptotic or proliferative response was established in a given cell line, a statistically significant loss of response in assays repeated three times in triplicate was considered evidence for antagonism. A true antagonistic response was differentiated from cellular toxicity by direct observation, trypan blue staining (a technique well known to one of normal skill in the art), or loss of acid phosphatase activity. Specificity of antagonism is assessed for each compound by evaluating whether the activity is demonstrated

20 against other proliferative agents such as interleukin 3 or interleukin 4.

25 [0099] Recombinant IL-9 and compounds potentially resembling IL-9 in structure or function were purified and prepared for use in the appropriate media. Putative agonists and antagonists were prepared in water, saline, or DMSO and water. Cells were used as is or after transfection with the IL-9 receptor constructs as described in Example 3. After 24 hrs of deprivation from growth factors, the cells were incubated without (control) or with variable amounts of purified

IL-9 and compounds potentially resembling IL-9 in structure or function.

30 [0100] Cell proliferation was assayed using the Abacus Cell Proliferation Kit (Clontech, Palo Alto, CA) which determines the amount of intracellular acid phosphatase present as an indication of cell number. The substrate p-nitrophenyl phosphate (pNPP) was converted by acid phosphatase to p-nitrophenol, which was measured as an indicator of enzyme concentration. pNPP was added to each well and incubated at 37°C for one hour. 1N sodium hydroxide was then added to stop the enzymatic reaction, and the amount of p-nitrophenol was quantified using a Dynatech 2000 plate reader (Dynatech Laboratories, Chantilly, VA) at 410 nm wavelength. Standard curves that compare cell number with optical absorbance were used to determine the linear range of the assay. Assay results were only used when absorbance measurements are within the linear range of the assay. Briefly, the assays were run with quadruplicate samples of cells in flat-bottom microtiter plates (150 or 200 microliter wells) with or without ligand for 72 to 96 hours at 37 degrees C. Acid phosphatase was used as a measure of the number of cells present. All experiments are repeated at least twice.

35 [0101] Apoptosis was assayed using the Annexin V kit as described by the supplier (Clontech) which determines dexamethasone-induced apoptosis by recognizing extracellular phosphatidylserine, an early marker for apoptosis. Apoptotic cell number was scored by fluorescence microscopy as a percentage of Annexin V stained cells.

40 [0102] The Mo7e line is a human megakaryoblastic cell line, cultured in RPMI 1640 (GIBCO/BRL, Gaithersburg, MD), 20% Fetal Bovine Serum (Hyclone) and 10 ng/ml IL-3 (R&D Systems, Minneapolis, MN). The T98G line is a human glioblastoma cell line grown in RPMI 1640 (GIBCO/BRL). The hamster fibroblast TK-ts13 line was also used as well as the murine 32D cell line, a murine myeloid precursor line, and both were cultured in RPMI 1640 (GIBCO/BRL) containing 10% fetal bovine serum (Hyclone) in addition 1 ng/ml m IL-3 was used with the 32 D cell lines. TF1.1 is a human myeloid leukemia line known to express the IL-2 receptor gamma subunit (confirmed by Western blots and rPCR), but, in comparison to its predecessor (TF1), it no longer bears IL-9 receptor by rPCR, immunostaining, and Western blot analyses. TF1.1 is cultured in RPMI 1640 (GIBCO/BRL) and 10% Fetal bovine serum (Hyclone). All the cell lines respond to multiple cytokines including IL-9. The cell lines were fed and reseeded at 2 X 10⁵ cells/ml every 72 hours.

45 [0103] The cells were centrifuged for 10 minutes at 2000 rpm and resuspended in RPMI 1640 with 0.5% Bovine Serum Albumin (GIBCO/BRL, Gaithersburg, MD) and insulin-transferrin-selenium (ITS) cofactors (GIBCO/BRL, Gaithersburg, MD). Cells were counted using a hemocytometer and diluted to a concentration of 1 X 10⁵ cells/ml and plated in a 96-well microtiter plate. Each well contained 0.15 or 0.2 ml, giving a final concentration of 10 to 50 thousand cells per well depending on the cell. Mo7e cells were stimulated with 50 ng/ml Stem Cell Factor (SCF) (R&D Systems, Minneapolis, MN) alone, 50 ng/ml SCF plus 50 ng/ml IL-3 (R&D Systems, Minneapolis, MN), or 50 ng/ml SCF plus 50 ng/ml IL-9. A control was included which contained cells and basal media only. Serial dilutions of test compounds (i.e., recombinant IL-9 proteins, peptides, small molecules) were added to each test condition in triplicate. TF1.1 cells that were not transfected with IL-9 receptors were used as an independent control for response and nonspecific cytotoxicity. Cultures were incubated for 72-96 hours at 37°C in 5% CO₂.

EXAMPLE 8

In situ & Western analysis of exogenous IL-9 receptor in transfected cell lines

5 [0104] *In situ* staining of the IL-9 receptor was carried out as follows. Cells were grown on coverslips for 24 hours and then coverslips containing the adherent cells were washed twice in phosphate buffered saline solution containing calcium and magnesium(PBS) (Gibco/BRL). For intracellular staining of the IL-9 receptor, the cells were fixed in 4% paraformaldehyde/PBS plus 0.1% triton-X for 15 minutes at room temperature before treatment with anti-human IL-9 receptor antibody; for extracellular staining, cells were treated with antibody before fixation. The cells were then washed
 10 twice in PBS and blocked with 7.5% BSA in dH₂O for 30 minutes at room temperature. PBS washed cells were then incubated with a 10 µg/ml solution of anti-human IL-9 receptor (polyclonal antibody directed against the carboxy terminus of the IL-9 receptor) in 1% BSA/PBS for 1 hour at room temperature. Cells were washed three times in PBS and then incubated in 10 µg/ml solution of an anti-rabbit rhodamine-conjugated antibody in 1% BSA/PBS for 30 minutes at room temperature. Cells were then washed three times in PBS and counter-stained using 1 µg/ml DAPI for 1 minute
 15 at room temperature. Cells were washed three times in dH₂O and fixed to a microscope slide and analyzed by fluorescence microscopy. The results for the transfected COS7 cells are shown in Figure 14.
 [0105] Western blots were performed on protein lysates obtained from direct lysis of cell extracts in 0.5% lysis buffer (Tris 50mM, NaCl 150 mM, NP40), 1 mM DTT and protease inhibitors) and boiled for 5 minutes. Samples were electrophoresed on 4-20% tris-glycine SDS gels (Novex) in tris-glycine running buffer. Proteins were then transferred to
 20 nitrocellulose by electroblot using the Trans Blot II apparatus (Bio Rad). After transfer, the membrane was blocked in TBS-T ((20 mM Tris, 137 mM NaCl, pH 7.6) plus 0.05% Tween 20) plus 5% blotto for 1 hour room temperature. Blots were then probed using a polyclonal antibody directed to the carboxy terminus of the IL-9 receptor (1 µg/ml) in TBS-T for 1 hour. Blots were then washed three times in TBS-T for 10 minutes and probed using a secondary anti-rabbit-horse radish peroxidase conjugated antibody (1:10,000) in TBS-T for 30 minutes. Blots were washed as above and
 25 then incubated with Luminol/enhancer solution (Pierce), a chemiluminescent substrate, for 5 minutes at room temperature and then exposed to film for 1-60 seconds. See Figures 11 and 12.

EXAMPLE 9

30 Methods for the Authentic IL-9R Genomic Amplification

35 [0106] Specific amplification of the authentic IL-9R (gene encoding for the biologically functional protein located in the XYq pseudoautosomal region) using standard primer design was not possible because IL-9R has four highly homologous (>90% nucleotide identity), nonprocessed pseudogenes at other loci in the human genome (chromosome 9, 10, 16, 18). Because of the high identity of these other genes, genomic PCR amplification using standard primer design resulted in co-amplification of all genes, thus making sequence analysis of the authentic gene equivocal. In order to study authentic IL-9R structure as it may relate to predisposition to disease such as asthma, discussed in this application, or other diseases such as cancer (Renauld, et al., Oncogene, 9:1327-1332, 1994; Gruss, et al., Cancer Res., 52:1026-1031, 1992), specific amplimers were designed as follows:

40 Sequences of the IL-9R pseudogene and authentic genes were aligned using Mac Vector software. Intronic sequences surrounding each exon were then inspected for regions of diversity between the authentic gene and pseudogenes. Primers were then designed against these regions, and used to PCR amplify human/rodent hybrid DNAs containing individual human chromosomes. Products were run on 3% agarose gels and analyzed for authentic IL-9R amplification with no amplification of the 4 pseudogenes. Specific PCR amplification conditions were also optimized by varying annealing temperature and buffer conditions (DMSO content 5-10%). In cases where amplification of pseudogenes still occurred, nucleotide changes were entered into primer sequences to cause greater divergence from the pseudogenes as compared to the authentic gene. Primer sequences are shown in Example 2 and their specificity is demonstrated in Figure 13.

50 EXAMPLE 10

Cell proliferation assay and cytokine stimulation

55 [0107] To determine growth response of TS1 cells expressing various forms of human IL-9 receptor, cells were washed with PBS and resuspended in D-MEM, 10% fetal bovine serum. 10³ cells per well were seeded in triplicate in 96-well microplates and, where appropriate, recombinant human IL-9 or murine IL-9 (R&D Systems, Minneapolis, MN) was added at a final concentration of 5 ng/ml. Cell proliferation was evaluated after 7 days using an acid phosphatase

assay. Briefly, 50 µl of a buffer containing 0.1M sodium acetate (pH 5.5), 0.1% Triton X-100 and 10mM p-nitrophenyl phosphate (Sigma 104 phosphatase substrate) was added per well. The plate was incubated for 1-1/2 hours at room temperature, the reaction stopped with 10 µl/well of 1N sodium hydroxide and the absorbance was read on a Dynatech Model MR600 at 410nm. To analyze tyrosine-phosphorylation of proteins of the signal transduction cascade upon cytokine stimulation, TS1 cells expressing various forms of human IL-9 receptor were washed with PBS, resuspended in D-MEM, 0.5% bovine serum albumin, and incubated for 6 hours at 37°C. Successively, 20 X 10⁶ cells were treated for 5 minutes with either human IL-9 or murine IL-9 (100 ng/ml) and immediately washed in cold PBS. Cells were lysed in RIPA buffer as described in Example 11.

10 EXAMPLE 11

Immunoprecipitations, immunoblotting and antibodies

15 [0108] Typically, 20-50 x 10⁶ cells were lysed in 1 ml of RIPA buffer (PBS containing 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 1mM PMSF, 50mM sodium fluoride, 1nM sodium orthovanadate, and 1x "Complete" protease inhibitors mixture, Cat. No. 1697498 Boehringer Mannheim) and incubated for 45 minutes on ice. Lysates were centrifuged for 20 minutes in an Eppendorf microcentrifuge and the supernatant recovered and transferred to a fresh tube. For immunoprecipitations, 1-5 µg of the antibody were added to the lysate and incubated overnight at 4°C. 20 ml of Protein A+G agarose-conjugated beads were added for 2 hrs followed by four washings using RIPA buffer. Beads were 20 resuspended in Laemmli buffer and boiled for 3 minutes before electrophoresis. Proteins were transferred onto Immobilon-P membrane (Millipore) and detected using a horseradish peroxidase-conjugated secondary antibody followed by a chemiluminescence detection assay (Pierce). Specific antibodies for murine and human IL-9 receptor (sc698), murine Jak1, Irs1, Irs2, Stat1, Stat2, Stat3, Stat4, Stat5, and phosphotyrosine (PY) were purchased from Santa Cruz (Santa Cruz, CA). Anti-Jak3 and monoclonal anti-human IL-9 receptor MAB290 were purchased from Upstate Biotechnology and R&D Systems, respectively. Figure 15 demonstrates the activation of members of the Jak family via different variants of the human IL-9 receptor.

EXAMPLE 12

30 Identification of IL-9 receptor genomic polymorphisms

35 [0109] Genomic DNAs were isolated from PBMCs of volunteer donors as described (Nicholaides and Stoeckert, Biotechniques 8:154-156, 1990). Sequence analysis of intron 5 of the human IL-9R gene was performed by PCR using primers of sequence ID NO 14 and sequence ID NO 17 which resulted in a product with the approximated molecular size of 1243 basepairs. Amplifications were carried out at 94°C for 30 seconds, 62°C for 1.5 minutes, 72°C for 1.5 minutes for 35 cycles in buffers described previously (Nicholaides et al., Genomics 30:195-206, 1995). Products were then purified and sequenced using a standard sequence protocol. Inspection of the sequences from intron 5 in multiple individuals found a nucleotide change at -213 nt upstream of exon 6 sequences which resulted in a thymidine (published sequence) to a cytosine nucleotide change. An example of this change is shown in figure 17.

40 [0110] While the invention has been described and illustrated herein by references to various specific materials, procedures and examples, it is understood that the invention is not restricted to the particular material combinations of material, and procedures selected for that purpose. Numerous variations of such details can be implied as will be appreciated by those skilled in the art.

45 REFERENCES

[0111]

- 50 1. Gergen PJ, and Weiss KB: The increasing problem of asthma in the United States. Am Rev Respir Dis 146: 823-824, 1992.
2. Goodman and Gilman's The Pharmacologic Basis of Therapeutics, Seventh Edition, MacMillan Publishing Company, N.Y. USA, 1985.
3. Burrows B, Martinez FD, Halonen M, Barbee RA, and Cline MG: Association of asthma with serum IgE levels and skin-test reactivity to allergens. New Eng J Med 320:271-277, 1989.
- 55 4. Clifford RD, Pugsley A, Radford M, and Holgate ST: Symptoms, atopy, and bronchial response to methacholine in parents with asthma and their children. Arch Dis in Childhood 62:66-73, 1987.
5. Gergen PJ: The association of allergen skin test reactivity and respiratory disease among whites in the U.S. population. Arch Intern Med 151:487-492, 1991.

6. Burrows B, Sears MR, Flannery EM, Herbison GP, and Holdaway MD: Relationship of bronchial responsiveness assessed by methacholine to serum IgE, lung function, symptoms, and diagnoses in 11-year-old New Zealand children. *J Allergy Clin Immunol* 90:376-385, 1992.
- 5 7. Johansson SGO, Bennich HH, and Berg T: The clinical significance of IgE. *Prog Clin Immunol* 1:1-25, 1972.
8. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, and Holdaway MD: Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children *New Engl J Med* 325 (15):1067-1071, 1991.
- 10 9. Halonen M, Stern D, Taussig LM, Wright A, Ray CG, and Martinez FD: The predictive relationship between serum IgE levels at birth and subsequent incidences of lower respiratory illnesses and eczema in infants. *Am Rev Respir Dis* 146:666-670, 1992.
- 10 10. Marsh DG, Meyers DA, and Bias WB: The epidemiology and genetics of atopic allergy. *New Eng J Med* 305: 1551-1559, 1982.
- 10 11. Hopp RJ, Bewtra AK, Biven R, Nair NM, Townley RG. Bronchial reactivity pattern in nonasthmatic parents of asthmatics. *Ann Allergy* 1988;61:184-186.
- 15 12. Hopp RJ, Townley RG, Biven RE, Bewtra AK, Nair NM. The presence of airway reactivity before the development of asthma. *Am Rev Respir Dis* 1990;141:2-8.
- 15 13. Ackerman V, Marini M, Vittori E, et al. Detection of cytokines and their cell sources in bronchial biopsy specimens from asthmatic patients: relationship to atopic status, symptoms, and level of airway hyperresponsiveness. *Chest* 1994;105:687-696.
- 20 14. Hamid G, Azzawi M, Ying S, et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. *J Clin Invest* 1991;87:1541-1546.
- 20 15. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. *Am Rev Respir Dis* 1990;142: 434-57.
- 25 16. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T lymphocyte population in atopic asthma. *N Engl J Med* 1992;326:298-304.
- 25 17. Robinson DS, Hamid Q, Ying S, et al. Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5, and interferon- γ cytokine gene expression. *Am Rev Respir Dis* 1993;148:401-406.
- 30 18. Robinson DS, Ying S, Bentley A, et al. Relationship among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in atopic asthma. *J Allergy Clin Immunol* 1993;92:397-403.
- 30 19. O'Connor GT, Sparrow D, and Weiss ST: The role of allergy and nonspecific BHR in the pathogenesis of COPD. *Am Rev Respir Dis* 140:225-252, 1989.
- 35 20. Cogswell JJ, Halliday DF, and Alexander JR: Respiratory infections in the first year of life in children at the risk of developing atopy. *Brit Med J* 284:1011-1013, 1982.
- 35 21. Boushey HA, Holtzman MJ, Sheller JR, and Nadel JA: BHR. *Am Rev Respir Dis* 121:389-413, 1980.
- 35 22. Renaud, J-C, Houssiau, F, Druez, C. Interleukin-9. *Int Rev Exp Pathology* 1993;34A: 99-109.
- 40 23. Renaud, J-C, Kermouni, A, Vink, A, Louahed, J, Van Snick, J. Interleukin-9 and its receptor: involvement in mast cell differentiation and T cell oncogenesis. *J Leukoc Biol* 1995;57:353-360.
- 40 24. Hultner, L, Moeller, J, Schmitt, E, Jager, G, Reisbach, G, Ring, J, Dormer, P. Thiol-sensitive mast cell lines derived from mouse bone marrow respond to a mast cell growth-enhancing activity different from both IL-3 and IL-4. *J Immunol* 1989;142:3440-3446.
- 45 25. Dugas, B, Renauld, J-C, Pene, J, Bonnefoy, J, Petit-Frere, C, Braquet, P, Bousquet, J, Van Snick, J, Mencia-Huerta, JM. Interleukin-9 potentiates the interleukin-4-induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytes. *Eur J Immunol* 1993;23:1687-1692.
- 45 26. Petit-Frere, C, Dugas, B, Braquet, P, Mencia-Huerta, JM. Interleukin-9 potentiates the interleukin-4-induced IgE and IgG1 release from murine B lymphocytes. *Immunology* 1993;79:146-151.
- 50 27. Behnke, JM, Wahid, FN, Grncis, RK, Else, KJ, Ben-Smith, AW, Goyal, PK. Immunological relationships during primary infection with *Heligmosomoides polygyrus* (*Nematospirodes dubius*): downregulation of specific cytokine secretion (IL-9 and IL-10) correlates with poor mastocytosis and chronic survival of adult worms. *Parasite Immunol* 1993;15:415-421.
- 50 28. Gessner, A, Blum, H, Rollinghoff, M. Differential regulation of IL-9 expression after infection with *Leischmania* major in susceptible and resistant mice. *Immunobiology* 1993;189:419-435.
- 55 29. Renaud J-C, Druez C, Kermouni A, et al. Expression cloning of the murine and human interleukin 9 receptor cDNAs. *Proc Natl Acad Sci* 89:5690-5694(1992).
- 55 30. Chang M-S, Engel G, Benedict C et al. Isolation and characterization of the Human interleukin-9 receptor gene. *Blood* 83:3199-3205(1994).
31. Renaud J-C, Goethals A, Houssiau F, et al. Human P40/IL-9. Expression in activated CD4+ T cells, Genomic

- Organization, and Comparison with the Mouse Gene. *J Immunol* 144:4235-4241(1990).
32. Kelleher K, Bean K, Clark SC, et al. Human interleukin-9: genomic sequence, chromosomal location, and sequences essential for its expression in human T-cell leukemia virus (HTLV-I-transformed human T cells. *Blood* 77:1436-1441(1991).
- 5 33. Houssiau FA, Schandene L, Stevens M, et al. A cascade of cytokines is responsible for IL-9 expression in human T cells. Involvement of IL-2, IL-4, and IL-10. *J of Immunol.* 154:2624-2630(1995).
34. Miyazawa K, Hendrie PC, Kim Y-J, et al. Recombinant human interleukin-9 induces protein tyrosine phosphorylation and synergizes with steel factor to stimulate proliferation of the human factor-dependent cell line, Mo7e. *Blood* 80:1685-1692(1992).
- 10 35. Yin T, Tsang M L-S, Yang Y-C. JAK1 kinase forms complexes with interleukin-4 receptor and 4PS/insulin receptor substrate-1-like protein and is activated by interleukin-4 and interleukin-9 in T lymphocytes. *J Biol Chem* 269:26614-26617(1994).
36. Zav'yalov VP, Navolotskaya EV, Isaev IS, et al. Nonapeptide corresponding to the sequence 27-35 of the mature human IL-2 efficiently competes with rIL-2 for binding to thymocyte receptors. *Immunol Lett* 31:285-288 (1992).
- 15 37. Chu JW, and Sharom FJ. Glycophorin A interacts with interleukin-2 and inhibits interleukin-2-dependent T-lymphocyte proliferation. *Cell Immunol* 145:223-239(1992).
38. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. *Lancet* 339:324-328(1992).
- 20 39. Morely J. Cyclosporin A in asthma therapy: a pharmacological rationale. *J Autoimmun* 5 Suppl A:265-269 (1992).
40. Sheffield VC, Beck JS, Kwitek AE, Sandstrom DW, and Stone EM: The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions. *Genomics* 16:325-332, 1993.
- 25 41. Orita M, Suzuki Y, Sekiya T, and Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. *Genomics* 5:874-9, 1989.
42. Sarkar G, Yoon H-S, and Sommer SS: Dideoxy fingerprint (ddF): A rapid and efficient screen for the presence of mutations. *Genomics* 13:441-443, 1992.
- 30 43. Cotton RG: Detection of single base changes in nucleic acids. *Biochemical Journal* 263(1):1-10, 1989.
44. Schwengel D, Nouri N, Meyers D, and Levitt RC: Linkage mapping of the human thromboxane A2 receptor (TBXA2R) to chromosome 19p13.3 using transcribed 3' untranslated DNA sequence polymorphisms. *Genomics* 18:212-215, 1993.
- 35 45. Cytokine Handbook, Angus Thomson (1994).
46. Nicolaides, N.C. and Stoecker, C.J. A simple, efficient method for the separate isolation of RNA and DNA from the same cells. *Biotechniques* 1996;8:154-156.
47. Ott J. Analysis of Human Genetic Linkage. Baltimore, Maryland: The Johns Hopkins University Press, 1991.
- 30 48. Meyers DA, Postma DS, Panhuysen CIM, et al. Evidence for a locus regulating total serum IgE levels mapping to chromosome 5. *Genomics* 1994;23:464 470.41.

40

45

50

55

SEQUENCE LISTING

5 (1) GENERAL INFORMATION:

(i) APPLICANT: MAGAININ, PHARMACEUTICALS INC.

10 (ii) TITLE OF INVENTION: IL-9 Receptor Variants, Useful in Treating
and Diagnosing Atopic Allergies Including Asthma
and Related Disorders

(iii) NUMBER OF SEQUENCES: 33

15 (iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30

20 (v) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER: PCT/US97/21992
- (B) FILING DATE: 02-DEC-1997
- (C) CLASSIFICATION:

25 (vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 60/032,224
- (B) FILING DATE: 02-DEC-1996

(vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 08/980,872
- (B) FILING DATE: 01-DEC-1997

35 (2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1947 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: cDNA

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

50

55

EP 1 471 144 A1

	AGCAGCTCTG TAATGCCCTT GTGGTTTCAG ATGTGGCGG CCTGTGTGAACCTGTCGTGC	60
5	AAAGCTCACG TCACCAACTG CTGCAGTTAT CTCCTGAATC AGGCTGAGGGCTTTGCTGT	120
	GCACCCAGAG ATAGTTGGGT GACAAATCAC CTCCAGGTTG GGGATGCCTCAGACTTGTGA	180
	TGGGACTGGG CAGATGCATC TGGGAAGGCT GGACCTTGGA GAGTGAGGCCCTGAGGCGAG	240
10	ACATGGGCAC CTGGCTCCTG GCCTGCATCT GCATCTGCAC CTGTGTCTGCTTGGGAGTCT	300
	CTGTCACAGG GGAAGGACAA GGGCCAAGGT CTAGAACCTT CACCTGCCTCACCAACAACA	360
	TTCTCAGGAT CGATTGCCAC TGGTCTGCC CAGAGCTGGG ACAGGGCTCCAGCCCCCTGGC	420
15	TCCTCTTCAC CAGCAACCAG GCTCCTGGCG GCACACATAA GTGCATCTTGGGGAGTGC	480
	AGTGCACCGT CGTGTGCCA CCTGAGGCAG TGCTCGTGC ATCTGACAATTCAACCATCA	540
	CTTTCCACCA CTGCATGTCT GGGAGGGAGC AGGTCAAGCCT GGTGGACCCGGAGTACCTGC	600
20	CCCGGAGACA CGTTAAGCTG GACCCGCCCT CTGACTTGCA GAGCAACATCAGTTCTGGCC	660
	ACTGCATCCT GACCTGGAGC ATCACTGCCTG CCTTGGAGCC AATGACCACACTTCTCAGCT	720
	ATGAGCTGGC CTTCAAGAAG CAGGAAGAGG CCTGGGAGCA GGCCCAGCACAGGGATCACA	780
25	TTGTCGGGGT GACCTGGCTT ATACTTGAAG CCTTGAGCT GGACCCCTGGCTTTATCCATG	840
	AGGCCAGGCT GCGTGTCCAG ATGCCACAC TGGAGGATGA TGTGGTAGAGGAGGAGCGTT	900
	ATACAGGCCA GTGGAGTGAG TGGAGCCAGC CTGTGTGCTT CCAGGCTCCCCAGAGACAAG	960
30	GCCCTCTGAT CCCACCCCTGG GGGTGGCCAG GCAACACCCCT TGTTGCTGTGCCATTTTC	1020
	TCCTGCTGAC TGGCCCGACC TACCTCCTGT TCAAGCTGTC GCCCAGGGTAAGAGAAATCT	1080
35	TCTACCAGAA CGTGCCTCT CCAGCGATGT TCTTCCAGCC CCTCTACAGTGTACACAATG	1140
	GGAACCTCCA GACTTGGATG GGGGCCACA GGGCCGGTGT GCTGTTGAGCCAGGACTGTG	1200
	CTGGCACCCC ACAGGGAGCC TTGGAGCCCT GCGTCCAGGA GGCCACTGCACTGCTCACTT	1260
40	GTGGCCCAGC GCGTCCTTGG AAATCTGTGG CCCTGGAGGA GGAACAGGAGGGCCCTGGGA	1320
	CCAGGCTCCC GGGGAACCTG AGCTCAGAGG ATGTGCTGCC AGCAGGGTGTACGGAGTGG	1380
	GGGTACAGAC GCTTGCTAT CTGCCACAGG AGGACTGGC CCCCACGTCCCTGACTAGGC	1440
45	CGGCTCCCCC AGACTCAGAG GGCAGCAGGA GCAGCAGCAG CAGCAGCAGCAGCAACA	1500
	ACAACAACTA CTGTGCCTTG GGCTGCTATG GGGGATGGCA CCTCTCAGCCCTCCCAGGAA	1560
	ACACACAGAG CTCTGGGCC ATCCCAGCCC TGGCCTGTGG CCTTCTTGTGACCATCAGG	1620
50	GCCTGGAGAC CCAGCAAGGA GTTGCCTGGG TGCTGGCTGG TCACTGCCAGAGGCCCTGGC	1680
	TGCATGAGGA CCTCCAGGGC ATGTTGCTCC CTTCTGTCCT CAGCAAGGCTCGGTCTGGA	1740
55	CATTCTAGGT CCCTGACTCG CCAGATGCAT CATGTCATT TTGGGAAAATGGACTGAAGT	1800

TTCTGGAGCC CTTGTCTGAG ACTGAACCTC CTGAGAAGGG GCCCCTAGCAGCGGTAGAG	1860
GTCCTGTCTG GATGGAGGCT GGAGGCTCCC CCCTCAACCC CTCTGCTCAGTGCCTGTGGG	1920
GAGCAGCCTC TACCCCTCAGC ATCCTGG	1947

(2) INFORMATION FOR SEQ ID NO:2:

- 10 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1947 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: cDNA

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AGCAGCTCTG TAATGCGCTT GTGGTTTCAG ATGTGGGCGG CCTGTGTGAACCTGTCGTGC	60
AAAGCTCACG TCACCAAATG CTGCAGTTAT CTCCTGAATC AGGCTGAGGGCTTTGCTGT	120
25 GCACCCAGAG ATAGTTGGGT GACAAATCAC CTCCAGGTTG GGGATGCCTCAGACTTGTGA	180
TGGGACTGGG CAGATGCATC TGGGAAGGCT GGACCTTGGGA GAGTGAGGCCCTGAGGCGAG	240
ACATGGGCAC CTGGCTCCTG GCCTGCATCT GCATCTGCAC CTGTGTCTGCTTGGGAGTCT	300
30 CTGTCACAGG GGAAGGACAA GGGCCAAGGT CTAGAACCTT CACCTGCCTCACCAACAACA	360
TTCTCAGGAT CGATTGCCAC TGGTCTGCC CAGAGCTGGG ACAGGGCTCCAGCCCCCTGGC	420
35 TCCTCTTCAC CAGCAACCAG GCTCCTGGCG GCACACATAA GTGCATCTTGCAGGGCAGTG	480
AGTGCACCGT CGTGCTGCCA CCTGAGGCAG TGCTCGTGC ATCTGACAATTTCACCATCA	540
CTTTCCACCA CTGCATGTCT GGGAGGGAGC AGGTCAGCCT GGTGGACCCGGAGTACCTGC	600
40 CCCGGAGACA CGTTAAGCTG GACCCGCCCT CTGACTTGCA GAGCAACATCAGTTCTGGCC	660
ACTGCATCCT GACCTGGAGC ATCAGTCCTG CCTTGGAGCC AATGACCACACTTCTCAGCT	720
ATGAGCTGGC CTTCAAGAAG CAGGAAGAGG CCTGGGAGCA GGCCCAGCACAGGGATCACA	780
45 TTGTCGGGGT GACCTGGCTT ATACTTGAAG CCTTGAGCT GGACCCCTGGCTTATCCATG	840
AGGCCAGGCT GCGTGTCCAG ATGGCCACAC TGGAGGATGA TGTGGTAGAGGAGGAGCGTT	900
ATACAGGCCA GTGGAGTGAG TGGAGCCAGC CTGTGTGCTT CCAGGCTCCCCAGAGACAAG	960
50 GCCCTCTGAT CCCACCCCTGG GGGTGGCCAG GCAACACCCCT TGTGCTGTGCCATTTCT	1020
TCCTGCTGAC TGGCCCGACC TACCTCCTGT TCAAGCTGTC GCCCAGGGTGAAGAGAAATCT	1080
TCTACCAGAA CGTGCCCTCT CCAGCGATGT TCTTCCAGCC CCTCTACAGTGTACACAATG	1140

55

	GGAACCTCCA GACTTGGATG GGGGCCACA GGGCCGGTGT GCTGTTGAGGCCAGGACTGTG	1200
5	CTGGCACCCCC ACAGGGAGCC TTGGAGCCCT GCGTCCAGGA GGCCACTGCACTGCTCACTT	1260
	GTGGCCCCAGC GCATCCTTGG AAATCTGTGG CCCTGGAGGA GGAACAGGAGGGCCCTGGGA	1320
	CCAGGCTCCC GGGGAACCTG AGCTCAGAGG ATGTGCTGCC AGCAGGGTGTACGGAGTGGA	1380
10	GGGTACAGAC GCTTGCTAT CTGCCACAGG AGGACTGGC CCCCACGTCCCTGACTAGGC	1440
	CGGCTCCCCC AGACTCAGAG GGCAGCAGGA GCAGCAGCAG CAGCAGCAGCAGCAACA	1500
	ACAACAACTA CTGTGCCTTG GGCTGCTATG GGGGATGGCA CCTCTCAGCCCTCCCAGGAA	1560
15	ACACACAGAG CTCTGGGCCCT ATCCCAGCCC TGGCCTGTGG CCTTTCTTGTGACCATCAGG	1620
	GCCTGGAGAC CCAGCAAGGA GTTGCCTGGG TGCTGGCTGG TCACTGCCAGAGGCCCTGGC	1680
	TGCATGAGGA CCTCCAGGGC ATGTTGCTCC CTTCTGTCTT CAGCAAGGCTCGGTCTGGA	1740
20	CATTCTAGGT CCCTGACTCG CCAGATGCAT CATGTCCATT TTGGGAAAATGGACTGAAGT	1800
	TTCTGGAGCC CTTGTCTGAG ACTGAACCTC CTGAGAAGGG GCCCCTAGCAGCGGTAGAG	1860
	GTCCTGTCTG GATGGAGGCT GGAGGCTCCC CCCTCAACCC CTCTGCTCAGTGCCTGTGGG	1920
25	GAGCAGCCTC TACCCCTCAGC ATCCTGG	1947

(2) INFORMATION FOR SEQ ID NO:3:

- 30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1944 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- 35 (ii) MOLECULE TYPE: cDNA

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

	AGCAGCTCTG TAATGCGCTT GTGGTTTCAG ATGTGGCGG CCTGTGTGAAACCTGTCGTGC	60
	AAAGCTCACG TCACCAAATG CTGCAGTTAT CTCCTGAATC AGGCTGAGGGTCTTGCTGT	120
45	GCACCCAGAG ATAGTTGGGT GACAAATCAC CTCCAGGTTG GGGATGCCTCAGACTTGTGA	180
	TGGGACTGGG CAGATGCATC TGGGAAGGCT GGACCTTGGA GAGTGAGGCCCTGAGGCGAG	240
	ACATGGGCAC CTGGCTCCTG GCCTGCATCT GCATCTGCAC CTGTGTCTGCTTGGGAGTCT	300
50	CTGTCACAGG GGAAGGACAA GGGCAAGGT CTAGAACCTT CACCTGCCTCACCAACAAACA	360
	TTCTCAGGAT CGATTGCCAC TGGTCTGCCCT CAGAGCTGGG ACAGGGCTCCAGGCCCTGGC	420
55	TCCTCTTCAC CAGCAACCAG GCTCCTGGCG GCACACATAA GTGCATCTTGCAGGGCAGTG	480

EP 1 471 144 A1

	AGTGCACCGT CGTGCTGCCA CCTGAGGCAG TGCTCGGCC ATCTGACAATTCAACCATCA	540
5	CTTTCCACCA CTGCATGTCT GGGAGGGAGC AGGTCAGCCT GGTGGACCCGGAGTACCTGC	600
	CCCGGAGACA CGTTAAGCTG GACCCGCCCT CTGACTTGCA GAGCAACATCAGTTCTGGCC	660
	ACTGCATCCT GACCTGGAGC ATCAGTCCTG CCTTGGAGCC AATGACCACACTTCAGCT	720
10	ATGAGCTGGC CTTCAAGAAG CAGGAAGAGG CCTGGGAGGC CCAGCACAGGGATCACATTG	780
	TCGGGGTGAC CTGGCTTATA CTTGAAGCCT TTGAGCTGGA CCCTGGCTTATCCATGAGG	840
	CCAGGCTGCG TGTCCAGATG GCCACACTGG AGGATGATGT GGTAGAGGAGGAGCGTTATA	900
15	CAGGCCAGTG GAGTGAGTGG AGCCAGCCTG TGTGCTTCCA GGCTCCCCAGAGACAAGGCC	960
	CTCTGATCCC ACCCTGGGGG TGGCCAGGCA ACACCCCTGT TGCTGTGTCCATCTTCTCC	1020
	TGCTGACTGG CCCGACCTAC CTCCTGTTCA AGCTGTCGCC CAGGGTGAAGAGAAATCTTCT	1080
20	ACCAAGAACGT GCCCTCTCCA GCGATGTTCT TCCAGCCCT CTACAGTGTACACAATGGGA	1140
	ACTTCCAGAC TTGGATGGGG GCCCACAGGG CCGGTGTGCT GTTGAGCCAGGACTGTGCTG	1200
	GCACCCACA GGGAGCCTTG GAGCCCTGCG TCCAGGAGGC CACTGCACTGCTCACTTGTG	1260
25	GCCCAGCGCG TCCTTGGAAA TCTGTGGCCC TGGAGGAGGA ACAGGAGGGCCCTGGGACCA	1320
	GGCTCCCGGG GAACCTGAGC TCAGAGGATG TGCTGCCAGC AGGGTGTACGGAGTGGAGGG	1380
	TACAGACGCT TGCCCTATCTG CCACAGGAGG ACTGGGCCCC CACGTCCCTGACTAGGCCGG	1440
30	CTCCCCCAGA CTCAGAGGGC AGCAGGAGCA GCAGCAGCAG CAGCAGCAGCAACAACA	1500
	ACAACACTTG TGCCCTGGGC TGCTATGGGG GATGGCACCT CTCAGCCCTCCAGGAAACA	1560
	CACAGAGCTC TGGGCCCATC CCAGCCCTGG CCTGTGGCCT TTCTTGTGACCATCAGGGCC	1620
	TGGAGACCCA GCAAGGAGTT GCCTGGGTGC TGGCTGGTCA CTGCCAGAGGCCCTGGCTGC	1680
	ATGAGGACCT CCAGGGCATG TTGCTCCCTT CTGTCCCTAG CAAGGCTCGGTCTGGACAT	1740
40	TCTAGGTCCC TGACTCGCCA GATGCATCAT GTCCATTG GGAAAATGGACTGAAGTTTC	1800
	TGGAGCCCTT GTCTGAGACT GAACCTCCTG AGAAGGGGCC CCTAGCAGCGGTCAAGAGGTC	1860
	CTGTCTGGAT GGAGGCTGGA GGCTCCCCC TCAACCCCTC TGCTCAGTGCCTGTGGGGAG	1920
45	CAGCCTCTAC CCTCAGCATH CTGG	1944

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1862 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

	AGCAGCTCTG TAATGCGCTT GTGGTTCAAG ATGTGGCGG CCTGTGTGAACCTGTCGTGC	60
10	AAAGCTCACG TCACCAACTG CTGCAGTTAT CTCCGTAAATC AGGCTGAGGGTCTTGCTGT	120
	GCACCCAGAG ATAGTTGGGT GACAAATCAC CTCCAGGTTG GGGATGCCTCAGACTTGTGA	180
	TGGGACTGGG CAGATGCATC TGGGAAGGCT GGACCTTGGA GAGTGAGGCCCTGAGGCAG	240
15	ACATGGGCAC CTGGCTCCTG GCCTGCATCT GCATCTGCAC CTGTGTCTGCTTGGAGTCT	300
	CTGTACAGG GGAAGGACAA GGGCCAAGGT CTAGAACCTT CACCTGCCTCACCAACAACA	360
20	TTCTCAGGAT CGATTGCCAC TGGTCTGCC CAGAGCTGGG ACAGGGCTCCAGCCCCCTGGC	420
	TCCTCTTCAC CAGCAACCAG GCTCCTGGCG GCACACATAA GTGCATCTTGCAGGGCAGTG	480
	AGTGCACCGT CGTGCTGCCA CCTGAGGCAG TGCTCGTGCC ATCTGACAATTTCACCATCA	540
25	CTTTCCACCA CTGCATGTCT GGGAGGGAGC AGGTCAAGCCT GGTGGACCCGGAGTACCTGC	600
	CCCGGAGACA CGTTAAGCTG GACCCGCCCT CTGACTTGCA GAGCAACATCAGTTCTGCC	660
	ACTGCATCCT GACCTGGAGC ATCAGTCCTG CCTTGGAGCC AATGACCACACTCTCAGCT	720
30	ATGAGCTGGC CTTCAAGAAG CAGGAAGAGG CCTGGGAGCA GGCCCAGCACAGGGATCACA	780
	TTGTCGGGGT GACCTGGCTT ATACTTGAAG CCTTGAGCT GGACCCCTGGCTTATCCATG	840
	AGGCCAGGCT GCGTGTCCAG ATGCCACAC TGGAGGATGA TGTGGTAGAGGGAGGAGCGTT	900
35	ATACAGGCCA GTGGAGTGAG TGGAGCCAGC CTGTGTGCTT CCAGGCTCCCCAGAGACAAG	960
	GCCCTCTGAT CCCACCCCTGG GGGTGGCCAG GCAACACCCCT TGTTGCTGTGTCATCTTC	1020
	TCCTGCTGAC TGGCCCGACC TACCTCCTGT TCAAGCTGTC GCCCAGACTGGATGGGGC	1080
40	CCACAGGGCC GGTGTGCTGT TGAGCCAGGA CTGTGTGGC ACCCCACAGGGAGCCTTGGA	1140
	GCCCTGCGTC CAGGAGGCCA CTGCACTGCT CACTTGTGGC CCAGCGCGTCCTTGGAAATC	1200
	TGTGCCCTG GAGGAGGAAC AGGAGGGCCC TGGGACCAGG CTCCCGGGAACCTGAGCTC	1260
45	AGAGGATGTG CTGCCAGCAG GGTGTACCGA GTGGAGGGTA CAGACGCTTGCCTATCTGCC	1320
	ACAGGAGGAC TGGGCCCCCA CGTCCCTGAC TAGGCCGGCT CCCCCAGACTCAGAGGGCAG	1380
	CAGGAGCAGC AGCAGCAGCA GCAGCAGCAG CAACAACAAC AACTACTGTGCCCTGGGCTG	1440
50	CTATGGGGGA TGGCACCTCT CAGCCCTCCC AGGAAACACA CAGAGCTCTGGCCCATCCC	1500
	AGCCCTGGCC TGTGGCCTTT CTTGTGACCA TCAGGGCCTG GAGACCCAGCAAGGAGTTGC	1560

55

	CTGGGTGCTG GCTGGTCACT GCCAGAGGCC TGGGCTGCAT GAGGACCTCCAGGGCATGTT	1620
	GCTCCCTTCT GTCCTCAGCA AGGCTCGGTC CTGGACATTC TAGGTCCTGACTGCCAGA	1680
5	TGCATCATGT CCATTTGGG AAAATGGACT GAAGTTCTG GAGCCCTGTCTGAGACTGA	1740
	ACCTCCTGAG AAGGGGCCAG TAGCAGCGGT CAGAGGT CCT GTCTGGATGGAGGCTGGAGG	1800
	CTCCCCCTC AACCCCTCTG CTCAGTGCCT GTGGGGAGCA GCCTCTACCCTCAGCATCCT	1860
10	GG	1862

(2) INFORMATION FOR SEQ ID NO:5:

- 15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 226 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- 20 (ii) MOLECULE TYPE: cDNA

	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:	
25	GCTGGACCTT GGAGAGTGAG GCCCTGAGGC GAGACATGGG CACCTGGCTCCTGGCCTGCA	60
	TCTGCATCTG CACCTGTGTC TGCTTGGGAG TCTCTGTAC AGGGGAAGGACAAGGGCAA	120
	GGTCTAGAAC CTTCACCTGC CTCACCAACA ACATTCTCAG GATCGATTGCCACTGGTCTG	180
30	CCCCAGAGCT GGGACAGGGC TCCAGCCCCCT GGCTCCTCTT CACCAG	226

(2) INFORMATION FOR SEQ ID NO:6:

- 35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 513 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- 40 (ii) MOLECULE TYPE: cDNA

	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:	
45	GCTGGACCTT GGAGAGTGAG GCCCTGAGGC GAGACATGGG CACCTGGCTCCTGGCCTGCA	60
	TCTGCATCTG CACCTGTGTC TGCTTGGGAG TCTCTGTAC AGGGGAAGGACAAGGGCAA	120
	GGTCTAGAAC CTTCACCTGC CTCACCAACA ACATTCTCAG GATCGATTGCCACTGGTCTG	180
50	CCCCAGAGCT GGGACAGGGC TCCAGCCCCCT GGCTCCTCTT CACCAGCAACCAGGCTCCTG	240
	GCGGCACACA TAAGTGCATC TTGCGGGGCA GTGAGTGCAC CGTCGTGCTGCCACCTGAGG	300

EP 1 471 144 A1

5	CAGTGCTCGT GCCATCTGAC AATTCACCA TCACTTCCA CCAC TGCATGTCTGGGAGGG	360
	AGCAGGTCAG CCTGGTGGAC CCGGAGTACC TGCCCCGGAG ACAC GCTGGACCCGCCCTCT	420
	GACTTGCAGA GCAACATCAG TTCTGCCAC TGCATCCTGA CCTGGAGCATCAGTCCTGCC	480
	TTGGAGCAA TGACCACACT TCTCAGCTAT GAG	513

10 (2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 513 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
15 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

25	GCTGGACCTT GGAGAGTGAG GCCCTGAGGC GAGACATGGG CACCTGGCTCCTGGCCTGCA	60
	TCTGCATCTG CACCTGTGTC TGCTTGGGAG TCTCTGTACAC AGGGGAAGGACAAGGGCCAA	120
	GGTCTAGAAC CTTCACCTGC CTCACCAACA ACATTCTCAG GATCGATTGCCACTGGTCTG	180
30	CCCCAGAGCT GGGACAGGGC TCCAGCCCT GGCTCCTCTT CACCAAGCAACCAGGCTCCTG	240
	GCGGCACACA TAAGTGCATC TTGCGGGGCA GTGAGTGCAC CGTCGTGCTGCCACCTGAGG	300
	CAGTGCTCGT GCCATCTGAC AATTCACCA TCACTTCCA CCAC TGCATGTCTGGGAGGG	360
35	AGCAGGTCAG CCTGGTGGAC CCGGAGTACC TGCCCCGGAG ACAC GAGCAACATCAGTTCT	420
	GGCCACTGCA TCCTGACCTG GAGCATCAGT CCTGCCCTGG AGCCAATGACCACACTTCTC	480
	AGCTATGAGC TGGCCTCAA GAAGCAGGAA GAG	513

40 (2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
45 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GCAGGGGGG ACCCATG

17

55

(2) INFORMATION FOR SEQ ID NO:9:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: other nucleic acid

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AGGCTTGACA TCGGACAAAC

19

(2) INFORMATION FOR SEQ ID NO:10:

- 20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: other nucleic acid

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CTGGCCTGAA GTACTTACC

19

(2) INFORMATION FOR SEQ ID NO:11:

- 35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: other nucleic acid

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CTGCTTCAAT CCTGGGGAA

19

(2) INFORMATION FOR SEQ ID NO:12:

- 50 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

55

(ii) MOLECULE TYPE: other nucleic acid

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GTGAGTTCCC CAGGATTGA

19

10 (2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: other nucleic acid

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CAAGGCCCTG CTCCAAA

17

25 (2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: other nucleic acid

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

TGGGGCTTCA GCCTCACATG

20

40 (2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: other nucleic acid

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

TATGTAGAGT GGGGAGTC

20

55

(2) INFORMATION FOR SEQ ID NO:16:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: other nucleic acid

15 (xii) SEQUENCE DESCRIPTION: SEQ ID NO:16:

TGTATTCTCG AGGGCTGAG

19

(2) INFORMATION FOR SEQ ID NO:17:

- 20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: other nucleic acid

30 (xiii) SEQUENCE DESCRIPTION: SEQ ID NO:17:

TGAGGTGAAC AGGGGAGAA

19

(2) INFORMATION FOR SEQ ID NO:18:

- 35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

40 (iii) MOLECULE TYPE: other nucleic acid

45 (xiv) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CCCTGGGCC TTCATGT

17

(2) INFORMATION FOR SEQ ID NO:19:

- 50 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 18 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

55

(ii) MOLECULE TYPE: other nucleic acid

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

ACAAGGGCGG CCTTTGAT

18

10 (2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

15

(iii) MOLECULE TYPE: other nucleic acid

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

AGGGACGAGG TGGGCGGAC

19

25 (2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

30

(iii) MOLECULE TYPE: other nucleic acid

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CCTGCCCCCC ATGTTCTT

18

40 (2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

45

(ii) MOLECULE TYPE: other nucleic acid

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

ATGCTACCTG AGCCCTTCC

19

55

(2) INFORMATION FOR SEQ ID NO:23:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: other nucleic acid

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GGACATGATG CATCTGGCG

19

(2) INFORMATION FOR SEQ ID NO:24:

- 20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1944 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: cDNA

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

AGCAGCTCTG TAATGCGCTT GTGGTTTCAG ATGTGGCGG CCTGTGTGAAACCTGTCGTGC	60
AAAGCTCACG TCACCAACTG CTGCAGTTAT CTCCTGAATC AGGCTGAGGGTCTTGCTGT	120
GCACCCAGAG ATAGTTGGGT GACAAATCAC CTCCAGGTTG GGGATGCCTCAGACTTGTGA	180
TGGGACTGGG CAGATGCATC TGGGAAGGCT GGACCTTGGA GAGTGAGGCCCTGAGGCGAG	240
ACATGGGCAC CTGGCTCCTG GCCTGCATCT GCATCTGCAC CTGTGTCTGCTTGGGAGTCT	300
CTGTCACAGG GGAAGGACAA GGGCCAAGGT CTAGAACCTT CACCTGCCTCACCAACAACA	360
TTCTCAGGAT CGATTGCCAC TGGTCTGCC CAGAGCTGGG ACAGGGCTCCAGCCCCCTGGC	420
TCCTCTTCAC CAGCAACCAG GCTCCTGGCG GCACACATAA GTGCATCTTGCAGGGCAGTG	480
AGTGCACCGT CGTGCTGCCA CCTGAGGCAG TGCTCGTGC ATCTGACAATTTCACCATCA	540
CTTTCCACCA CTGCATGTCT GGGAGGGAGC AGGTCAGCCT GGTGGACCCGGAGTACCTGC	600
CCCGGAGACA CGTTAAGCTG GACCCGCCCT CTGACTTGCA GAGCAACATCAGTTCTGCC	660
ACTGCATCCT GACCTGGAGC ATCAGTCCTG CCTTGGAGCC AATGACCACACTTCTCAGCT	720
55 ATGAGCTGGC CTTCAAGAAG CAGGAAGAGG CCTGGGAGGC CCAGCACAGGGATCACATTG	780

	TCGGGGTGAC CTGGCTTATA CTTGAAGCCT TTGAGCTGGA CCCTGGCTTATCCATGAGG	840
5	CCAGGCTGCG TGTCCAGATG GCCACACTGG AGGATGATGT GGTAGAGGAGGAGCGTTATA	900
	CAGGCCAGTG GAGTGAGTGG AGCCAGCCTG TGTGTTCCA GGCTCCCCAGAGACAAGGCC	960
	CTCTGATCCC ACCCTGGGGG TGGCCAGGCA ACACCCTGT TGCTGTGTCCATCTTCTCC	1020
10	TGCTGACTGG CCCGACCTAC CTCCCTGTTCA AGCTGTCGCC CAGGGTGAAGAGAAATCTTCT	1080
	ACCAAGAACGT GCCCTCTCCA GCGATGTTCT TCCAGCCCC CTACAGTGTACACAATGGGA	1140
	ACTTCCAGAC TTGGATGGGG GCCCACAGGG CCGGTGTGCT GTTGAGGCCAGGACTGTGCTG	1200
15	GCACCCCCACA GGGAGCCTTG GAGCCCTGCG TCCAGGAGGC CACTGCACTGCTCACTTGTG	1260
	GCCCAGCGCG TCCTTGGAAA TCTGTGGCCC TGGAGGAGGA ACAGGAGGGCCCTGGGACCA	1320
	GGCTCCCGGG GAACCTGAGC TCAGAGGATG TGCTGCCAGC AGGGTGTACGGAGTGGAGGG	1380
20	TACAGACGCT TGCCTATCTG CCACAGGAGG ACTGGGCCCC CACGTCCCTGACTAGGCCGG	1440
	CTCCCCCAGA CTCAGAGGGC AGCAGGAGCA GCAGCAGCAG CAGCAGCAGCAGCAACAACA	1500
	ACAAACTACTG TGCCTTGGGC TGCTATGGGG GATGGCACCT CTCAGCCCTCCCAGGAAACA	1560
25	CACAGAGCTC TGGGCCATC CCAGCCCTGG CCTGTGGCCCT TTCTTGTGACCATCAGGGCC	1620
	TGGAGACCCA GCAAGGAGTT GCCTGGGTGC TGGCTGGTCA CTGCCAGAGGCCTGGCTGC	1680
	ATGAGGACCT CCAGGGCATG TTGCTCCCTT CTGTCTCAG CAAGGCTCGGTCTGGACAT	1740
30	TCTAGGTCCC TGACTCGCCA GATGCATCAT GTCCATTGG GGAAAATGGACTGAAGTTTC	1800
	TGGAGCCCTT GTCTGAGACT GAACCTCTG AGAAGGGGCC CCTAGCAGGGTCAGAGGTC	1860
35	CTGTCTGGAT GGAGGCTGGA GGCTCCCCC TCAACCCCTC TGCTCAGTGCCTGTGGGAG	1920
	CAGCCTCTAC CCTCAGCCTAC CTGG	1944

(2) INFORMATION FOR SEQ ID NO:25:

40 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: other nucleic acid

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

GCTGGACCTT GGAGAGTG

18

(2) INFORMATION FOR SEQ ID NO:26:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: other nucleic acid

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GTCTCAGACA AGGGCTCCAG

20

(2) INFORMATION FOR SEQ ID NO:27:

- 20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 501 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: peptide

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Met Gly Thr Trp Leu Leu Ala Cys Ile Cys Ile Cys Thr Cys Val Cys
 1 5 10 15

Leu Gly Val Ser Val Thr Gly Glu Gly Gln Gly Pro Arg Ser Arg Thr
 20 25 30

Phe Thr Cys Leu Thr Asn Asn Ile Leu Arg Ile Asp Cys His Trp Ser
 35 40 45

Ala Pro Glu Leu Gly Gln Gly Ser Ser Pro Trp Leu Leu Phe Thr Ser
 50 55 60

Asn Gln Ala Pro Gly Gly Thr His Lys Cys Ile Leu Arg Gly Ser Glu
 65 70 75 80

Cys Thr Val Val Leu Pro Pro Glu Ala Val Leu Val Pro Ser Asp Asn
 85 90 95

Phe Thr Ile Thr Phe His His Cys Met Ser Gly Arg Glu Gln Val Ser
 100 105 110

Leu Val Asp Pro Glu Tyr Leu Pro Arg Arg His Val Lys Leu Asp Pro
 115 120 125

Pro Ser Asp Leu Gln Ser Asn Ile Ser Ser Gly His Cys Ile Leu Thr
 130 135 140

EP 1471 144 A1

Trp Ser Ile Ser Pro Ala Leu Glu Pro Met Thr Thr Leu Leu Ser Tyr
 145 150 155 160
 5 Glu Leu Ala Phe Lys Lys Gln Glu Glu Ala Trp Glu Gln Ala Gln His
 165 170 175
 Arg Asp His Ile Val Gly Val Thr Trp Leu Ile Leu Glu Ala Phe Glu
 180 185 190
 10 Leu Asp Pro Gly Phe Ile His Glu Ala Arg Leu Arg Val Gln Met Ala
 195 200 205
 Thr Leu Glu Asp Asp Val Val Glu Glu Glu Arg Tyr Thr Gly Gln Trp
 210 215 220
 15 Ser Glu Trp Ser Gln Pro Val Cys Phe Gln Ala Pro Gln Arg Gln Gly
 225 230 235 240
 Pro Leu Ile Pro Pro Trp Gly Trp Pro Gly Asn Thr Leu Val Ala Val
 245 250 255
 20 Ser Ile Phe Leu Leu Leu Thr Gly Pro Thr Tyr Leu Leu Phe Lys Leu
 260 265 270
 25 Ser Pro Arg Val Lys Arg Ile Phe Tyr Gln Asn Val Pro Ser Pro Ala
 275 280 285
 Met Phe Phe Gln Pro Leu Tyr Ser Val His Asn Gly Asn Phe Gln Thr
 290 295 300
 30 Trp Met Gly Ala His Arg Ala Gly Val Leu Leu Ser Gln Asp Cys Ala
 305 310 315 320
 Gly Thr Pro Gln Gly Ala Leu Glu Pro Cys Val Gln Glu Ala Thr Ala
 325 330 335
 35 Leu Leu Thr Cys Gly Pro Ala Arg Pro Trp Lys Ser Val Ala Leu Glu
 340 345 350
 Glu Glu Gln Glu Gly Pro Gly Thr Arg Leu Pro Gly Asn Leu Ser Ser
 355 360 365
 40 Glu Asp Val Leu Pro Ala Gly Cys Thr Glu Trp Arg Val Gln Thr Leu
 370 375 380
 Ala Tyr Leu Pro Gln Glu Asp Trp Ala Pro Thr Ser Leu Thr Arg Pro
 385 390 395 400
 45 Ala Pro Pro Asp Ser Glu Gly Ser Arg Ser Ser Ser Ser Ser Ser
 405 410 415
 Ser Ser Asn Asn Asn Asn Tyr Cys Ala Leu Gly Cys Tyr Gly Gly Trp
 420 425 430
 50 His Leu Ser Ala Leu Pro Gly Asn Thr Gln Ser Ser Gly Pro Ile Pro
 435 440 445
 Ala Leu Ala Cys Gly Leu Ser Cys Asp His Gln Gly Leu Glu Thr Gln
 450 455 460

Gln Gly Val Ala Trp Val Leu Ala Gly His Cys Gln Arg Pro Gly Leu
 465 470 475 480

5 His Glu Asp Leu Gln Gly Met Leu Leu Pro Ser Val Leu Ser Lys Ala
 485 490 495

Arg Ser Trp Thr Phe
 500

10 (2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 501 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

25 Met Gly Thr Trp Leu Leu Ala Cys Ile Cys Ile Cys Thr Cys Val Cys
 1 5 10 15

Leu Gly Val Ser Val Thr Gly Glu Gly Gln Gly Pro Arg Ser Arg Thr
 20 25 30

30 Phe Thr Cys Leu Thr Asn Asn Ile Leu Arg Ile Asp Cys His Trp Ser
 35 40 45

35 Ala Pro Glu Leu Gly Gln Gly Ser Ser Pro Trp Leu Leu Phe Thr Ser
 50 55 60

Asn Gln Ala Pro Gly Gly Thr His Lys Cys Ile Leu Arg Gly Ser Glu
 65 70 75 80

40 Cys Thr Val Val Leu Pro Pro Glu Ala Val Leu Val Pro Ser Asp Asn
 85 90 95

Phe Thr Ile Thr Phe His His Cys Met Ser Gly Arg Glu Gln Val Ser
 100 105 110

45 Leu Val Asp Pro Glu Tyr Leu Pro Arg Arg His Val Lys Leu Asp Pro
 115 120 125

Pro Ser Asp Leu Gln Ser Asn Ile Ser Ser Gly His Cys Ile Leu Thr
 130 135 140

50 Trp Ser Ile Ser Pro Ala Leu Glu Pro Met Thr Thr Leu Leu Ser Tyr
 145 150 155 160

55 Glu Leu Ala Phe Lys Lys Gln Glu Glu Ala Trp Glu Gln Ala Gln His
 165 170 175

Arg Asp His Ile Val Gly Val Thr Trp Leu Ile Leu Glu Ala Phe Glu
 180 185 190
 5 Leu Asp Pro Gly Phe Ile His Glu Ala Arg Leu Arg Val Gln Met Ala
 195 200 205
 Thr Leu Glu Asp Asp Val Val Glu Glu Glu Arg Tyr Thr Gly Gln Trp
 210 215 220
 10 Ser Glu Trp Ser Gln Pro Val Cys Phe Gln Ala Pro Gln Arg Gln Gly
 225 230 235 240
 Pro Leu Ile Pro Pro Trp Gly Trp Pro Gly Asn Thr Leu Val Ala Val
 245 250 255
 15 Ser Ile Phe Leu Leu Leu Thr Gly Pro Thr Tyr Leu Leu Phe Lys Leu
 260 265 270
 Ser Pro Arg Val Lys Arg Ile Phe Tyr Gln Asn Val Pro Ser Pro Ala
 275 280 285
 20 Met Phe Phe Gln Pro Leu Tyr Ser Val His Asn Gly Asn Phe Gln Thr
 290 295 300
 Trp Met Gly Ala His Arg Ala Gly Val Leu Leu Ser Gln Asp Cys Ala
 25 305 310 315 320
 Gly Thr Pro Gln Gly Ala Leu Glu Pro Cys Val Gln Glu Ala Thr Ala
 325 330 335
 Leu Leu Thr Cys Gly Pro Ala His Pro Trp Lys Ser Val Ala Leu Glu
 30 340 345 350
 Glu Glu Gln Glu Gly Pro Gly Thr Arg Leu Pro Gly Asn Leu Ser Ser
 355 360 365
 Glu Asp Val Leu Pro Ala Gly Cys Thr Glu Trp Arg Val Gln Thr Leu
 35 370 375 380
 Ala Tyr Leu Pro Gln Glu Asp Trp Ala Pro Thr Ser Leu Thr Arg Pro
 385 390 395 400
 40 Ala Pro Pro Asp Ser Glu Gly Ser Arg Ser Ser Ser Ser Ser Ser
 405 410 415
 Ser Ser Asn Asn Asn Asn Tyr Cys Ala Leu Gly Cys Tyr Gly Gly Trp
 420 425 430
 45 His Leu Ser Ala Leu Pro Gly Asn Thr Gln Ser Ser Gly Pro Ile Pro
 435 440 445
 Ala Leu Ala Cys Gly Leu Ser Cys Asp His Gln Gly Leu Glu Thr Gln
 50 450 455 460
 Gln Gly Val Ala Trp Val Leu Ala Gly His Cys Gln Arg Pro Gly Leu
 465 470 475 480
 His Glu Asp Leu Gln Gly Met Leu Leu Pro Ser Val Leu Ser Lys Ala
 55 485 490 495

Arg Ser Trp Thr Phe
500

(2) INFORMATION FOR SEQ ID NO:29:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 500 amino acids
 (B) TYPE: amino acid
 10 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Met Gly Thr Trp Leu Leu Ala Cys Ile Cys Ile Cys Thr Cys Val Cys
20 1 5 10 15

Leu Gly Val Ser Val Thr Gly Glu Gly Gln Gly Pro Arg Ser Arg Thr
25 20 25 30

Phe Thr Cys Leu Thr Asn Asn Ile Leu Arg Ile Asp Cys His Trp Ser
25 35 40 45

Ala Pro Glu Leu Gly Gln Gly Ser Ser Pro Trp Leu Leu Phe Thr Ser
30 50 55 60

Asn Gln Ala Pro Gly Gly Thr His Lys Cys Ile Leu Arg Gly Ser Glu
35 65 70 75 80

Cys Thr Val Val Leu Pro Pro Glu Ala Val Leu Val Pro Ser Asp Asn
35 85 90 95

Phe Thr Ile Thr Phe His His Cys Met Ser Gly Arg Glu Gln Val Ser
35 100 105 110

Leu Val Asp Pro Glu Tyr Leu Pro Arg Arg His Val Lys Leu Asp Pro
40 115 120 125

Pro Ser Asp Leu Gln Ser Asn Ile Ser Ser Gly His Cys Ile Leu Thr
45 130 135 140

Trp Ser Ile Ser Pro Ala Leu Glu Pro Met Thr Thr Leu Leu Ser Tyr
45 145 150 155 160

Glu Leu Ala Phe Lys Lys Gln Glu Glu Ala Trp Glu Ala Gln His Arg
50 165 170 175

Asp His Ile Val Gly Val Thr Trp Leu Ile Leu Glu Ala Phe Glu Leu
55 180 185 190

Asp Pro Gly Phe Ile His Glu Ala Arg Leu Arg Val Gln Met Ala Thr
55 195 200 205

EP 1471 144 A1

Leu Glu Asp Asp Val Val Glu Glu Glu Arg Tyr Thr Gly Gln Trp Ser
 210 215 220
 5 Glu Trp Ser Gln Pro Val Cys Phe Gln Ala Pro Gln Arg Gln Gly Pro
 225 230 235 240
 Leu Ile Pro Pro Trp Gly Trp Pro Gly Asn Thr Leu Val Ala Val Ser
 245 250 255
 10 Ile Phe Leu Leu Leu Thr Gly Pro Thr Tyr Leu Leu Phe Lys Leu Ser
 260 265 270
 Pro Arg Val Lys Arg Ile Phe Tyr Gln Asn Val Pro Ser Pro Ala Met
 15 275 280 285
 Phe Phe Gln Pro Leu Tyr Ser Val His Asn Gly Asn Phe Gln Thr Trp
 290 295 300
 20 Met Gly Ala His Arg Ala Gly Val Leu Leu Ser Gln Asp Cys Ala Gly
 305 310 315 320
 Thr Pro Gln Gly Ala Leu Glu Pro Cys Val Gln Glu Ala Thr Ala Leu
 325 330 335
 25 Leu Thr Cys Gly Pro Ala Arg Pro Trp Lys Ser Val Ala Leu Glu Glu
 340 345 350
 Glu Gln Glu Gly Pro Gly Thr Arg Leu Pro Gly Asn Leu Ser Ser Glu
 355 360 365
 30 Asp Val Leu Pro Ala Gly Cys Thr Glu Trp Arg Val Gln Thr Leu Ala
 370 375 380
 Tyr Leu Pro Gln Glu Asp Trp Ala Pro Thr Ser Leu Thr Arg Pro Ala
 385 390 395 400
 35 Pro Pro Asp Ser Glu Gly Ser Arg Ser Ser Ser Ser Ser Ser Ser Ser
 405 410 415
 Ser Asn Asn Asn Asn Tyr Cys Ala Leu Gly Cys Tyr Gly Gly Trp His
 420 425 430
 40 Leu Ser Ala Leu Pro Gly Asn Thr Gln Ser Ser Gly Pro Ile Pro Ala
 435 440 445
 45 Leu Ala Cys Gly Leu Ser Cys Asp His Gln Gly Leu Glu Thr Gln Gln
 450 455 460
 Gly Val Ala Trp Val Leu Ala Gly His Cys Gln Arg Pro Gly Leu His
 465 470 475 480
 50 Glu Asp Leu Gln Gly Met Leu Leu Pro Ser Val Leu Ser Lys Ala Arg
 485 490 495
 55 Ser Trp Thr Phe
 500

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:

 - (A) LENGTH: 286 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Met	Gly	Thr	Trp	Leu	Leu	Ala	Cys	Ile	Cys	Ile	Cys	Thr	Cys	Val	Cys
1				5					10				15		
Leu	Gly	Val	Ser	Val	Thr	Gly	Glu	Gly	Gln	Gly	Pro	Arg	Ser	Arg	Thr
				20					25				30		
Phe	Thr	Cys	Leu	Thr	Asn	Asn	Ile	Leu	Arg	Ile	Asp	Cys	His	Trp	Ser
				35				40				45			
Ala	Pro	Glu	Leu	Gly	Gln	Gly	Ser	Ser	Pro	Trp	Leu	Leu	Phe	Thr	Ser
				50			55				60				
Asn	Gln	Ala	Pro	Gly	Gly	Thr	His	Lys	Cys	Ile	Leu	Arg	Gly	Ser	Glu
				65			70			75				80	
Cys	Thr	Val	Val	Leu	Pro	Pro	Glu	Ala	Val	Leu	Val	Pro	Ser	Asp	Asn
				85					90				95		
Phe	Thr	Ile	Thr	Phe	His	His	Cys	Met	Ser	Gly	Arg	Glu	Gln	Val	Ser
				100				105					110		
Léu	Val	Asp	Pro	Glu	Tyr	Leu	Pro	Arg	Arg	His	Val	Lys	Leu	Asp	Pro
				115				120				125			
Pro	Ser	Asp	Leu	Gln	Ser	Asn	Ile	Ser	Ser	Gly	His	Cys	Ile	Leu	Thr
				130			135				140				
Trp	Ser	Ile	Ser	Pro	Ala	Leu	Glu	Pro	Met	Thr	Thr	Leu	Leu	Ser	Tyr
				145			150			155				160	
Glu	Leu	Ala	Phe	Lys	Lys	Gln	Glu	Glu	Ala	Trp	Glu	Gln	Ala	Gln	His
				165				170				175			
Arg	Asp	His	Ile	Val	Gly	Val	Thr	Trp	Leu	Ile	Leu	Glu	Ala	Phe	Glu
				180				185				190			
Leu	Asp	Pro	Gly	Phe	Ile	His	Glu	Ala	Arg	Leu	Arg	Val	Gln	Met	Ala
				195				200				205			
Thr	Leu	Glu	Asp	Asp	Val	Val	Glu	Glu	Glu	Arg	Tyr	Thr	Gly	Gln	Trp
					210			215				220			
Ser	Glu	Trp	Ser	Gln	Pro	Val	Cys	Phe	Gln	Ala	Pro	Gln	Arg	Gln	Gly
				225				230			235			240	

Pro Leu Ile Pro Pro Trp Gly Trp Pro Gly Asn Thr Leu Val Ala Val
 245 250 255

5 Ser Ile Phe Leu Leu Leu Thr Gly Pro Thr Tyr Leu Leu Phe Lys Leu
 260 265 270

Ser Pro Arg Leu Gly Trp Gly Pro Thr Gly Pro Val Cys Cys
 275 280 285

10 (2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 64 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

25 Met Gly Thr Trp Leu Leu Ala Cys Ile Cys Ile Cys Thr Cys Val Cys
 1 5 10 15

Leu Gly Val Ser Val Thr Gly Glu Gly Gln Gly Pro Arg Ser Arg Thr
 20 25 30

30 Phe Thr Cys Leu Thr Asn Asn Ile Leu Arg Ile Asp Cys His Trp Ser
 35 40 45

Ala Pro Glu Leu Gly Gln Gly Ser Ser Pro Trp Leu Leu Phe Thr Ser
 50 55 60

35 (2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 128 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

50 Met Gly Thr Trp Leu Leu Ala Cys Ile Cys Ile Cys Thr Cys Val Cys
 1 5 10 15

Leu Gly Val Ser Val Thr Gly Glu Gly Gln Gly Pro Arg Ser Arg Thr
 20 25 30

55

Phe Thr Cys Leu Thr Asn Asn Ile Leu Arg Ile Asp Cys His Trp Ser
 35 40 45
 Ala Pro Glu Leu Gly Gln Gly Ser Ser Pro Trp Leu Leu Phe Thr Ser
 5 50 55 60
 Asn Gln Ala Pro Gly Gly Thr His Lys Cys Ile Leu Arg Gly Ser Glu
 65 70 75 80
 Cys Thr Val Val Leu Pro Pro Glu Ala Val Leu Val Pro Ser Asp Asn
 10 85 90 95
 Phe Thr Ile Thr Phe His His Cys Met Ser Gly Arg Glu Gln Val Ser
 15 100 105 110
 Leu Val Asp Pro Glu Tyr Leu Pro Arg Arg His Ala Gly Pro Ala Leu
 115 120 125

20 (2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 150 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

30
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
 Met Gly Thr Trp Leu Leu Ala Cys Ile Cys Ile Cys Thr Cys Val Cys
 35 1 5 10 15
 Leu Gly Val Ser Val Thr Gly Glu Gly Gln Gly Pro Arg Ser Arg Thr
 20 25 30
 Phe Thr Cys Leu Thr Asn Asn Ile Leu Arg Ile Asp Cys His Trp Ser
 40 35 40 45
 Ala Pro Glu Leu Gly Gln Gly Ser Ser Pro Trp Leu Leu Phe Thr Ser
 45 50 55 60
 Asn Gln Ala Pro Gly Gly Thr His Lys Cys Ile Leu Arg Gly Ser Glu
 65 70 75 80
 Cys Thr Val Val Leu Pro Pro Glu Ala Val Leu Val Pro Ser Asp Asn
 50 85 90 95
 Phe Thr Ile Thr Phe His His Cys Met Ser Gly Arg Glu Gln Val Ser
 55 100 105 110
 Leu Val Asp Pro Glu Tyr Leu Pro Arg Arg His Glu Gln His Gln Phe

Trp Pro Leu His Pro Asp Leu Glu His Gln Ser Cys Leu Gly Ala Asn
130 135 140

5 Asp His Thr Ser Gln Leu
145 150

10

Claims

1. An isolated nucleic acid encoding human interleukin-9 (IL-9) receptor, characterized in that said nucleic acid molecule is selected in the group consisting of a DNA molecule or a RNA molecule in which nucleotides corresponding to the first 29 nucleotides of exon 5 have been deleted, and fragments or complements thereof containing the deletion.
2. The isolated nucleic acid of claim 1 wherein the fragment having the deletion encodes a protein or peptide that binds IL-9.
3. The isolated nucleic acid of claim 1 wherein the fragment containing the deletion encodes substantially the amino acid sequence depicted in figure 7.
4. The isolated nucleic acid of claim 1 wherein the nucleotide sequence comprises the sequence represented at figure 7.
5. The isolated nucleic acid of claim 1 wherein the nucleotide sequence consists of the sequence represented at figure 7.
6. The isolated nucleic acid of claim 1 wherein the DNA is cDNA.
7. The isolated nucleic acid of claim 1 wherein the RNA is mRNA.
8. A vector comprising the nucleic acid of any one of claims 1 to 7.
- 35 9. The vector of claim 8 comprising a plasmid, cosmid or virus.
10. The vector of claim 8 that is a recombinant or expression vector.
- 40 11. The vector of claim 8 further comprising a regulatory sequence.
12. The vector of claim 11 wherein the regulatory sequence is a promoter, ribosomal binding site or transcription termination site.
- 45 13. The vector of claim 12 wherein the promoter is selected from the group consisting of human cytomegalovirus promoter, tetracycline-inducible promoter, simian virus promoter, moloney murine leukemia virus long terminal repeat promoter, glucocorticoid inducible murine mammary tumor virus promoter, herpes thymidine kinase promoter, murine and human-actin promoters, HTLV1 and HIC IL-9 5' flanking region, human or mouse IL-9 receptor 5' flanking region, bacterial tac promoter or *Drosophila* heat shock protein scaffold attachment region (SAR) enhancer elements.
- 50 14. The host cell transformed by the vector of any of claims 8 to 13.
15. The host cell of claim 14 that is transformed by infection, direct uptake, transduction, F-mating, microinjection or electroporation.
- 55 16. The host cell of claim 14 that is selected from the group consisting of bacterial cells, yeast cells, insect cells, plant cells and mammalian cells.

17. The host cell of claim 16 that is selected from the group consisting of *E. coli*, *Pseudomonas*, *Bacillus*, *Streptomyces*, CHO, R1-1, B-W, LH, COS-J, COS-7, BSC1, BSC40, BMT10 or S69 cells.
- 5 18. The host cell of claim 16 wherein the yeast cells are selected from the group consisting of *Saccharomyces*, *Pichia*, *Candida*, *Hansenula* or *Torulopsis*.
19. An isolated human IL-9 receptor protein encoded by the isolated nucleic acid of claim 1.
- 10 20. The protein of claim 19 comprising the amino acid sequence depicted in figure 7
21. The protein of claim 19 consisting of amino acid sequence depicted in figure 7.
- 15 22. The protein of any one of claims 19 to 21 that binds IL-9.
23. The protein of claim 22 that is soluble.
24. A method of making a protein comprising culturing a host cell transformed with the nucleic acid of any one of claims 1 to 7 under conditions in which the protein encoded by said nucleic acid is expressed.
- 20 25. A protein produced by the method of claim 24.
26. Use of the nucleic acid of claim 1 or the protein of claim 19 for preparation of a medicament for the treatment of atopic allergy.
- 25 27. Use of the nucleic acid of claim 1 or the protein of claim 19 wherein the atopic allergy is asthma.
28. The use according to claim 26 or 27 wherein the medicament alleviates an antigen-induced symptom.
29. The use according to claim 26 or 27 wherein the medicament improves pulmonary function.
- 30 30. The use according to claim 27, 28 or 29 wherein the medicament alleviates a symptom of asthma selected from the group consisting of bronchial hyperresponsiveness, eosinophilia, airflow obstruction, rhinitis, urticaria, inflammatory disorders of the bowel, elevated cell counts in bronchial lavage or elevated serum IgE.
- 35 31. The use of claim 27, 28 or 29 wherein the medicament causes a decrease in bronchial hyperresponsiveness.
32. The use of claim 27, 28 or 29 wherein the medicament causes a decrease in inflammatory cells.
33. The use of claim 27, 28 or 29 wherein the inflammatory cells are selected from the group consisting of mast cells, eosinophils, epithelial cells or T-lymphocytes.
- 40 34. The use according to claim 27, 28 or 29 wherein the medicament is formulated for intravenous, intramuscular, subcutaneous, topical, inhalation, sublingual or oral administration.
- 35 35. The use of claim 34 wherein the oral medicament is a tablet or capsule.
36. The use of claim 34 wherein the topical medicament is a cream, lotion, ointment or shampoo.
37. The use of claim 34 wherein the inhaled medicament is a liquid or powder.
- 50 38. The use of claim 37 wherein the inhaled medicament is administered by a nebulizer or inhaler.
39. The use of claim 38 wherein the nebulizer is a small volume nebulizer.
- 55 40. The use of claim 39 wherein the inhaler is a metered dose inhaler.
41. The use according to claim 34 wherein the medicament is administered at a dose of about 0.01 to about 100 mg/kg.

EP 1 471 144 A1

42. The use according to claim 41 wherein the medicament is administered at a dose of about 0.1 to about 10 mg/kg.

5

10

15

20

25

30

35

40

45

50

55




FIG. 1

SEQUENCE RANGE: 243 TO 1944

FIG. 2-1

1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200 1210 1220
 * * * * * * * * * * * * * * * * *
 TCTACAGA CCTGCCCTT CCACCATGT TTTCAGCC CCTCACAT GTACCTCA GAACTTCA GACTGATG GGGCCCCACA GGCCCCCTGT CCTGTCAGCTC CAGGACTTC CTGCGACCC ACUGGAGCC
 F Y Q N V P S P A W F F Q P L Y S V H N G N F Q T W H G A H R A G V L L S Q D C A G T P Q G A>
 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320 1330 1340 1350 1360
 * * * * * * * * * * * * * * * * *
 TGGAGCCCT GGCCTGAGA CGCTACATG CTGCTGAGA GGAAGAGAG GGGCTTGGAA CTGGCTTGT GGGAACTG AGCTGAGG ATGGTGTC
 L E P C V Q E A T A L L T C G P A R P W K S V A L E E E Q B G P G T R L P G N L S S E D V L P>
 1370 1380 1390 1400 1410 1420 1430 1440 1450 1460 1470 1480 1490 1500
 * * * * * * * * * * * * * * * * *
 ACCAGGTTT AGCGAGCTGA GGTTACGAC GTTGGCTAT CCTCCAGAG AGGACTGGC CCCACACTCC CCACTAGCC CCACTCCCTC AGACTCAG GGGCTGGAA GGGGGGGC GAGGGGCC ACCAACACA
 A G C T E W R V Q T L A Y L P Q E D W A P T S L T R P A P P D S E G S R S S S S S S S S N>
 1510 1520 1530 1540 1550 1560 1570 1580 1590 1600 1610 1620 1630 1640
 * * * * * * * * * * * * * * * * *
 AGAACTAC TCCCTGGGC TCTATGGGG GATGGACCT CCTAGACCTC CACAGAACAA CACAGAACAA CCTGGCCATG CAGGCTCC CCTGTCGCTT TCTTGAC CATGACCC TGAGGAGTT
 N N Y C A L G C Y G G W H L S A L P G N T Q S S G P I P A L A C G L S C D H Q G L E T Q Q G V>
 1650 1660 1670 1680 1690 1700 1710 1720 1730 1740 1750 1760 1770 1780
 * * * * * * * * * * * * * * * * *
 CCTGGCTCC TCCCTGGCA CCTGGGGAGG CCTGGGGCTT CCTGGGGCTT CCTGGGGCTT CCTGGGGCTT CCTGGGGCTT CCTGGGGCTT CCTGGGGCTT CCTGGGGCTT CCTGGGGCTT
 A W V L A G H C Q R P G L H E D L Q G M L L P S V L S K A R S W T F V P D S P D A S C P F W>
 1790 1800 1810 1820 1830 1840 1850 1860 1870 1880 1890 1900 1910 1920
 * * * * * * * * * * * * * * * * *
 GGAATGCA CGAGGTTT TGGAGCCCT GTCTGAGCT GAACTCTG CCTGGAGCC GGGCTGGAA GGCTGGCCCT TGAACCTTC TGCTGAGTC CTGCTGGAG
 E N G L K F L E P L S E T E P P E K G P L A A V R G P V W M E A G C S P L N P S A Q C L W G>
 1930 1940
 * * * * *
 CAGCTCTAC CCTGGACAT CTGG
 A A S T L S I L>

FIG. 2-2

SEQUENCE RANGE: 243 TO 1944

250 260 270 280 290 300 310 320 330 340 350 360 370 380
* * * * * * * * * * * * * * * * * * *
ATGGGCACTGGGTCTG GCGTGCAC CGATCGATCT CGTGTGTCGC TTGGAGGT CTGTCACAGG GGAAACAA GGGCAGCT CTTGACCTT CACTGCCAC
N G T W L L A C I C I C T C V C L G V S V T G E C Q G P R S R T F T C L T N N I L R I D C H>
390 400 410 420 430 440 450 460 470 480 490 500 510 520
* * * * * * * * * * * * * * * * * *
TGTCCTCCC CAGACCTGG AGCGGCTGC AGCCCTTCAC CACCAACAGG GTCTCTGG GCACACATAA GTTCATTCG CCGGGAGT AGTGACCTT CGTCCTGCC
W S A P E L G O G S S P W L L F T S N O A P G G T H K C I L R G S E C T V V L P P E A V L V P,
530 540 550 560 570 580 590 600 610 620 630 640 650 660
* * * * * * * * * * * * * * * * * *
ATCTGACAT TTACACATAA CTTCACACCA CTGCTGCTG AGCTGAGGC AGGTGAGGC GGTGACCTG GGTGACCTT GGTGACCTG GACCGCTT CTGACTGCA GACCAACAT AGTTCGCC
S D N P T I T F H H C W S G R E Q V S L V D P E Y L P R R H V K L D P P S D L Q S N I S S G>
670 680 690 700 710 720 730 740 750 760 770 780 790 800
* * * * * * * * * * * * * * * * * *
ACTGCTCT GACCTGGAGC ATCACTCTCT CCTTGACCC ATTGACCAAC CTCACAGG CTCACAGG CCTGGAGG CCTGGAGG AGCTGGCTT GACCTGGCTT
H C I L T W S I S P A L E P W T T L L S Y E L A F K K Q E E A W E Q A Q H R D H I V G V T W L>
810 820 830 840 850 860 870 880 890 900 910 920 930 940
* * * * * * * * * * * * * * * * * *
ATCTTGAG CCTTGAGT GGACCTGG TTATACCTG AGGACAGCT GGTGCTGCAG ATGGACAC TGGAGCTT ATAGAGCTA GTGGAGCTG TGAAGCTAC CTCGCTGCTT
I L E A F E L D P G F I H E A R L R V Q M A T L E D D V V E E R Y T G Q W S E W S Q P V C P>
950 960 970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
* * * * * * * * * * * * * * * * * *
CCAGGCTCC CAGAGCAGG GCGCTCTAT CCACACCTGG GGTGGCAG CTAACACCTT TTCTGCTAC TCCCGAAC TACCTCTGT TCAAGCTCTG GCGACCTG AAGAACATCT
Q A P Q R Q G P L I P P W G W P G N T L V S I F L L T G P T Y L L P K L S P R V K R I>

FIG. 3-1

FIG. 3-2

SEQUENCE RANGE: 243 TO 1103

* 250 * 260 * 270 * 280 * 290 * 300 * 310 * 320 * 330 * 340 * 350 * 360 * 370 * 380
 ATGGGAC CCTGCCTCG GCCTGAACT GGTCTGAC CTTGCTTCG TTGGAGCTT CTGTCACAG GGAGGAAA GGCGAAGT CTGAACTT CACCTCTT ACCAACAAAC TTCTAGAT CGATGCCAC
 H G T W L L A C I C I C V C L G V S V T G E G Q G P R S R T F T C L T N N I L R I D C H>
 * 390 * 400 * 410 * 420 * 430 * 440 * 450 * 460 * 470 * 480 * 490 * 500 * 510 * 520
 TGGTCCGCC CAGACCTGG ACAGGCTTC AGGCCCCTGC AGGCCCCTGC TCCTCTCAC CAGAACCCAG GTGCTCTGGC GCAACATAA GTGCTCTG OGEGEGCTG AGTGCACGTT CTCTCTGCC
 W S A P E L G Q G S S P W L L F T S N Q A P G G T H K C I L R G S E C T V V L P P E A V L V P>
 * 530 * 540 * 550 * 560 * 570 * 580 * 590 * 600 * 610 * 620 * 630 * 640 * 650 * 660
 ATCTGACATT TTGACCATTA CTTGACATCTT GGGAGGAGC AGGTCAAGCTT ATAGCTGCTT CTTGACCCS GAGTCACTSC CCGGGAGCA CCTTAAGACA GGTGACTCAT ACTTCTGCC
 S D N F T I T F H H C W S G R E Q V S L V D P E Y L P R R H V K L D P P S D L Q S N I S S G>
 * 670 * 680 * 690 * 700 * 710 * 720 * 730 * 740 * 750 * 760 * 770 * 780 * 790 * 800
 ACTGATCTT GAGCTGGAGC ATCACTCTG CCTCTCACCT ATAGCTGCTT CTTGAGAG GGGAGGAGG CCTGGAGACA AGGGAGGAC AGGGAGGCTT GAGCTGGCTT
 H C I L T W S I S P A L E P W T T L L S Y E L A F K K Q E E A W E Q A Q H R D H I V G V T W L>
 * 810 * 820 * 830 * 840 * 850 * 860 * 870 * 880 * 890 * 900 * 910 * 920 * 930 * 940
 ATACTGAGG CCTTGAGCT GGACCCCTGC TTTATCAGT AGGGCAGCTT GCGTGTCAAG ATGGCACAC TGGAGGATCA TGTCTAGIC GAGGAGCTT ATAGGACCA GTGAGCTGAG TGGAGGAGC CTGCTGCTT
 I L E A F E L D P G F I H E A R L R V Q W A T L E D D V V E E R Y T G Q W S E W S Q P V C F>
 * 950 * 960 * 970 * 980 * 990 * 1000 * 1010 * 1020 * 1030 * 1040 * 1050 * 1060 * 1070 * 1080
 CGAGGCTCC CAGACACAG GCCTCTGAT CCCACCTGG GGTGGGAG GCACACCTT TCTCTCTC TCCATCTTC TCACTCTGT TCACTCTGT GCACTGACTT GAACTGGGC
 Q A P Q R Q G P L I P P W G W P G N T L V A V S I F L L T G P T Y L L P R L S P R L G W G>
 * 1090 * 1100
 CCAAGGGCC GGTGCTGT TGA
 P T G P V C C ,>

FIG. 4

SEQUENCE RANGE: 243 TO 1944

250 260 270 280 290 300 310 320 330 340 350 360 370 380
 * * * * * * * * * * * * * * * * * * *
 ATGGGAC CTCGCTCTG GCCTGCAT CTGATCTCAC ACCTGGACTCT CTGTCACAGG GAAAGGACCA GGGCTAAGT CTGACACTT GACCTCTC ACCAACATA TCTCAGGAT CATTGCCAC
 W G T W L L A C I C I C V C L G V S V T G E G Q G P R S R T F T C L T N N I L R I D C H >
 390 400 410 420 430 440 450 460 470 480 490 500 510 520
 * * * * * * * * * * * * * * * * * * *
 TGTCTGCC CAGAGCTGG AGACGGCTGC AGCCGGCTGC CCCTCTTCAGG CGGCTACATAA GTGCGATTTG CGGGGGAGTG AGTGACCGT CCTGCTGCA CCTGAGGAG TGCGTGCC
 W S A P E L G Q G S S P W L L F T S N Q A P G G T H K C I L R G S E C T V V L P P E A V L V P
 530 540 550 560 570 580 590 600 610 620 630 640 650 660
 * * * * * * * * * * * * * * * * * *
 ATCTGACAT TTACCATCA CTTTCACCA CTGCGATGCT GGGAGGAGC AGGTAGCT GTGGAACCC CGCTACTGGC CGGTAAAGTC GACCCCGCTT CTGACTTGA GAGGACATC AGTCTGCC
 S D N F T I T P H H C W S G R E Q V S L V D P E Y L P R R H V K L D P P S D L Q S N I S S G >
 670 680 690 700 710 720 730 740 750 760 770 780 790 800
 * * * * * * * * * * * * * * * * * *
 ACTGACATCT GACGGAGC ATCACTCTG CCTGGAGCC AATGACCA CTTCTGAGT ATGACCTGC CTCAGAGG CAGGAAGG CCTGGAGGC CGAGGAGG GATCACATG TGCGCTAAC CTGGCTATA
 H C I L T W S I S P A L E P W T T L L S Y E L A F K K Q E E A W B A Q H R D H I V G V T W L I >
 810 820 830 840 850 860 870 880 890 900 910 920 930 940
 * * * * * * * * * * * * * * * * * *
 CTTGAACCT TTACCTCA CCCTGCTT ATTCTGAGG CGGAGCTGG TTGAGCTGG AGGAGATGT GTTACAGTG GAGCTATA GAGCTACTG GAGCTACTG AGCTCTCA
 L E A F E L D P G F I H E A R L R V Q M A T L E D V V E E R Y T G Q W S E W S Q P V C F Q
 950 960 970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
 * * * * * * * * * * * * * * * * * *
 GGCTCCAG AGACAGGCC CTCGATCC ACCCTGGGG TGGCGACCA ACACCTGTCTC AGCTTCTC AGCTCTCTC AGCTCTCA AGCTCTCC CAGGCTACAG AGATCTCT
 A P Q R Q G P L I P P W G W P G N T L V A V S I F L L L T G P T Y L L F K L S P R V K R I P >

FIG. 5-1

1090 * 1100 * 1110 * 1120 * 1130 * 1140 * 1150 * 1160 * 1170 * 1180 * 1190 * 1200 * 1210 * 1220 *
 ACCAGAEST GCGCTTCA GCGATTTCT TCGAGCCT CTACAGTGTG CACATGGAA ACTTCAGAC N F Q P L Y S V H N G N F Q T W W G A H R A G V L L S Q D C A G T P Q G A L>
 Y Q N V P S P A M F F 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320 1330 1340 1350 1360
 * *
 GAGGCTCG TCAGAGGC CACTGACTG CTACATG GCGCGCCG TCCCTGGAA TCTCTGGAA ATCTGGGCC CCTGGACCA GCTCTGGG GAACTGAGC TGAAGGATC TCTTCAGC
 E P C V Q E A T A L L T C G P A R P W K S V A L E E Q E G P G T R L P G N L S S E D V L P A>
 1370 1380 1390 1400 1410 1420 1430 1440 1450 1460 1470 1480 1490 1500
 * *
 AGGTCTAG GACTGAGGG TACAGACCT TCCATTCTG CGCTGGCCC ACTGGCCC CAGCTCCG ACTAGCTCG CTCCTAGA CTCAGAGGC AGCTGGGC CCTGGAGG
 G C T E W R V Q F L A Y L P Q E D W A P T S L T R P A P P D S E G S R S S S S S S S S N N>
 1510 1520 1530 1540 1550 1560 1570 1580 1590 1600 1610 1620 1630 1640
 * *
 ACAGACTG TGCTTGCC TCTCTGGGG GATGGACT CTAGGCTCT CGAGAGTC TGGCCATC CGAGCTGC CCTGGGGCT TTCTGGAC CATCTGGC TGGAGCTA GAAAGCT
 N N Y C A L G C Y G G W H L S A L P G N T Q S S G P I P A L A C G L S C D H Q G L E T Q Q G V>
 1650 1660 1670 1680 1690 1700 1710 1720 1730 1740 1750 1760 1770 1780
 * *
 GCGCTGGC TGCTGGCTA CTGCGAGG CCTGGGGCTC ATGGGACT TGGCTCTG CGAGGATG TGGCTCTG CGAGGCTG TGGAGAT TCTAGTCC TCTCGCA GATGGCT GTCTTTC
 A W V L A G H C Q R P G L H E D L Q G M L L P S V L S K A R S W T P V P D S P D A S C P P W>
 1790 1800 1810 1820 1830 1840 1850 1860 1870 1880 1890 1900 1910 1920
 * *
 GCGAATGGA CTGAGTTC TGGACCTT GTCTGACT GAACTCTG AGAGGGCTG CCTGGAGGC GTGAGGTC CTGCTGAT GAACTGGA GCTGGGGAG
 P N G L K F L E P L S E T E P P E K G P L A A V R G P V W W E A G G S P L N P S A Q C L W G>
 1930 1940
 * *
 CAGCTCTAC CCTACCATC CTGG
 A A S T L S I L>

FIG. 5-2

210 GCACTTGA GAGTGGCC CTGAGGGC ACATGGGC CTTGGCTTC CCTCCATCT GCAATTGAC CGTGTTCGCTT
 GCT 220 230 240 250 260 270 280 290 300 310 320 330
 M G T W L L A C I C I C T C V C L G V S V T G E G Q G P R>
 340 350 360 370 380 390 400 410 420 430 440 450 460
 CTAGAACCTT CACCTGGCT ACCAACACA TTCTGGAT CTTTGGCAC TGGTCTGCG CAGAGCTGG ACAGGCTCC AGGCCCTGC
 S R T F T C L T N N I L R I D C H W S A P E L G Q G S S P W L L F T S N Q A P G G T H K>
 470 480 490 500 510 520 530 540 550 560 570 580 590
 GTGCAATTC CGGGCGCTG AGTCACCGT CGCTCTCCA CCTGAGCG AGTCTGCG ATCTGACAT TTCAACATA CTTCACAA
 C I L R G S E C T V V L P P E A V L V P S D N F T L T F H H C M S G R E Q V S L V D P>
 600 610 620 630 640 650 660 670 680 690 700 710 720
 GAGTACCTC CCCGAGACA CGCTGGCCC GCCTCTGAC TTCCAGCA ACATGGTC CCTGGCTTG GACCTGACT CCTGAGCT
 E Y L P R R H A G P A L>

FIG. 6

210 220 230 240 250 260 270 280 290 300 310 320 330
 CCT GAACTTGG AAGTGGCC CTGAGGCC ACATGGAC CGCTGTCT GCCTGACTT GATCTGGAC CGTGTCTGC TGGCAAGCT CTCAGACG
 H G T W L L A C I C I C T C V C I G V S V T G E C Q G P R>
 340 350 360 370 380 390 400 410 420 430 440 450 460
 CTGAACTT CACCTTCC ACCAACACA TTCTTGGAT CGATTGCCAC TGGTGTGCC CAGGCTGG ACAGGATCC AGCCCTGGC TCCCTTCAG CAGAACATRA
 S R T F T C L T N N I L R I D C H W S A P E L G Q G S S P W L L F T S N Q A P G G T H K>
 470 480 490 500 510 520 530 540 550 560 580 590
 GTCGACTTG CGGGGAGTC AGTCGACCGT CGTGTGCC CGTGGGGAG CGTGTGCC ATCTGACAT TCTACCATCA CTTCCACCA CGCGATCTT GGGAGCCG
 C I L R G S E C T V V L P P E A V L V P S D N F T I T F H H C N S G R Y Q V S L V D P>
 600 610 620 630 640 650 660 670 680 690 700 710 720
 GACTACCTGC CGCGGAGACA CGAGGACAT CAGTGTGC CAGTGTGC TGACCTGGAG CATAGACCT GCTTGGAGC CAATGACAC ACTCTCAGC TATGAGCTG CCTTCAAGAA CGCGGAGAG

E Y L P R R H E Q H Q F W P L H P D L R H Q S C L G A N D H T S Q D>

FIG. 7

SEQUENCE RANGE: 243 TO 437

250 260 270 280 290 300 310 320 330 340 350 360 370 380
 * * * * * * * * * * * * * *
 ATGGCCAC CTCCTCTCTC CCCTGCAAT GCAATGCCAC CTTCAGCTGC TTGGAGCTC TTCTTGACCTT GTCAGCTGC ACCTGGCTC ACCAACACA TTCTCAGGAT CGATTGCCAC
 W G T W L L A C I C I C T C V C L G V S V T G E G Q G P R S R T F T C L T N N I L R I D C H
 390 400 410 420 430
 * * * * * * * * * * * *
 TGTTCTGCC CAGAGCTGGG AGAGGGTCC AGCCCTGCC TCCCTCTAC CAGTAA
 W S A P E L G Q G S S P W L L F T S †>

FIG. 8

INTERLEUKIN-9 RECEPTOR VARIANTS

<u>PHENOTYPE</u>	<u>GENOTYPE</u>		
ALLERGIC	ARG/ARG 1/18	ARG/HIS 8/18*	HIS/HIS 1/18*
NONALLERGIC	7/18	1/18	0/18

FISHER EXACT TEST P=0.002**

* INCLUDES ASTHMATICS
** ASSUMES ALLERGY IS AUTOSOMAL DOMINANT TRAIT

FIG. 9




FIG. 10




FIG. II




FIG. 12




FIG. 13




FIG. 14A-1

FIG. 14C-1

FIG. 14E-1

FIG. 14G-1

FIG. 14I-1

FIG. I4B-1



FIG. I4D-1

FIG. I4F-1

FIG. I4H-1

FIG. I4J-1




FIG. I4A-2

FIG. I4C-2

FIG. I4E-2

FIG. I4G-2

FIG. I4I-2

FIG. 14B-2



FIG. 14D-2



FIG. 14F-2



FIG. 14H-2



FIG. 14J-2




FIG. 15A



FIG. 15B




FIG. 15C



FIG. 15D




FIG. 15E




FIG. 15F



FIG. 15G






FIG. 16

INTRON 5 POLYMORPHISM OF THE HUMAN IL-9 RECEPTOR

	90	100	110	120	130	↓ 140	150	
WT HUMAN IL-9 RECEPTOR SEQUENCE	AAGTGTGATG AGTGTGAAG TGTTCCTGTA GACATGTTG CCTGTGCTG CATACTGTA TTGTGGCA>							
MUTANT IL-9 RECEPTOR SEQUENCE	AAGTGTGATG AGTGTGAAG TGTTCCTGTA GACATGTTG CCTGTGCTG CATACTGTA TTGTGGCA							
WT HUMAN IL-9 RECEPTOR SEQUENCE	AAGTGTGATG AGTGTGAAG TGTTCCTGTA GACATGTTG CCTGTGCTG CACAATGTA TTGTGGCA>							
MUTANT IL-9 RECEPTOR SEQUENCE	AAGTGTGATG AGTGTGAAG TGTTCCTGTA GACATGTTG CCTGTGCTG CATACTGTA TTGTGGCA							

FIG. 17



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 04 01 3403

DOCUMENTS CONSIDERED TO BE RELEVANT									
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)						
P,X	WO 97/08321 A (MAGAININ PHARMA) 6 March 1997 (1997-03-06) * page 26, line 17 - line 35 * * claims 28,37 *	19,22-25	C12N15/12 C07K14/715 C12Q1/68 G01N33/68 G01N33/566 A61K38/17 C12N5/10 C12N15/11						
A	RENAULD J.-C. ET AL.: "Expression cloning of the murine and human interleukin 9 receptor cDNAs." PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 5690-5694, XP002065134 see Fig. 3 and 4 and discussion	1-42							
A,D	KERMOUNI A. ET AL.: "The IL-9 receptor gene (IL9R): Genomic structure, chromosomal localization in the pseudoautosomal region of the long arm of the sex chromosomes, and identification of IL9R pseudogenes at 9qter, 10pter, 16pter and 18 pter." GENOMICS, vol. 29, no. 2, 1995, pages 371-382, XP002065133 see the whole document, especially page 380, right column, 2nd paragraph	1-42							
A	WO 92/05698 A (LUDWIG INST CANCER RES ;SCRAS (FR)) 16 April 1992 (1992-04-16) * page 1, last paragraph - page 2, paragraph 2 * * page 3, paragraph 2 *	1-42	C12N C07K C12Q G01N A61K						
<p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 34%;">Examiner</td> </tr> <tr> <td>Munich</td> <td>27 July 2004</td> <td>Mandl, B</td> </tr> </table> <p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>				Place of search	Date of completion of the search	Examiner	Munich	27 July 2004	Mandl, B
Place of search	Date of completion of the search	Examiner							
Munich	27 July 2004	Mandl, B							



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 04 01 3403

DOCUMENTS CONSIDERED TO BE RELEVANT									
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)						
A	<p>MEYERS D. A. ET AL.: "EVIDENCE FOR A LOCUS REGULATING TOTAL SERUM IGE LEVELS MAPPING TO CHROMOSOME 5" GENOMICS, vol. 23, no. 2, 15 September 1994 (1994-09-15), pages 464-470, XP000616442 * the whole document *</p> <p>-----</p> <p>HOLGATE S. T.: "GENETIC AND ENVIRONMENTAL INFLUENCES ON AIRWAY INFLAMMATION IN ASTHMA" INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol. 107, no. 1/03, May 1995 (1995-05), pages 29-33, XP000616471 * the whole document *</p> <p>-----</p>	1-42							
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)						
<p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 33%;">Examiner</td> </tr> <tr> <td>Munich</td> <td>27 July 2004</td> <td>Mandl, B</td> </tr> </table> <p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>				Place of search	Date of completion of the search	Examiner	Munich	27 July 2004	Mandl, B
Place of search	Date of completion of the search	Examiner							
Munich	27 July 2004	Mandl, B							

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 04 01 3403

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

27-07-2004

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9708321	A	06-03-1997	AU	6895696 A	19-03-1997
			CA	2230240 A1	06-03-1997
			EP	0846173 A1	10-06-1998
			JP	11514851 T	21-12-1999
			WO	9708321 A1	06-03-1997
			US	6261559 B1	17-07-2001
			US	2004076607 A1	22-04-2004
			US	5908839 A	01-06-1999
			US	6037149 A	14-03-2000
			US	2002146391 A1	10-10-2002
			ZA	9607182 A	25-05-1998
<hr/>					
WO 9205698	A	16-04-1992	US	5132109 A	21-07-1992
			AT	182079 T	15-07-1999
			AT	234632 T	15-04-2003
			AU	5243493 A	17-02-1994
			AU	646509 B2	24-02-1994
			AU	8760791 A	28-04-1992
			CA	2093434 A1	06-04-1992
			DE	69131450 D1	19-08-1999
			DE	69131450 T2	30-03-2000
			DE	69133225 D1	24-04-2003
			DE	69133225 T2	19-02-2004
			DK	553198 T3	27-12-1999
			DK	903150 T3	21-07-2003
			EP	0553198 A1	04-08-1993
			EP	0903150 A1	24-03-1999
			ES	2136065 T3	16-11-1999
			ES	2194273 T3	16-11-2003
			GR	3031518 T3	31-01-2000
			JP	3205754 B2	04-09-2001
			JP	6502404 T	17-03-1994
			JP	2001253835 A	18-09-2001
			WO	9205698 A1	16-04-1992
			US	5246701 A	21-09-1993
<hr/>					

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.